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IDENTIFYING OR MEASURING SELECTED 
SUBSTANCES OR TOXINS IN A SUBJECT 
USING RESONANT RAMAN SIGNALS 
RELATED APPLICATIONS 
This application is a continuation-in-part of International 
Patent Application Serial No. PCT/US/02/00649, filed Jan. 
9, 2002, which is a continuation-in-part of U.S. application 
Ser. No. 091756,897, filed Jan. 9, 2001 now U.S. Pat. No. 
6,574,501, the disclosures of which are hereby incorporated 
by reference as if restated in their entireties herein. 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 5 202) in which 
the Contractor has elected to retain title. The United States 
Government has certain rights to this invention. 
FIELD OF THE INVENTION 
The present invention concerns methods and apparatus for 
measuring or identifying the presence of selected substances 
in the body of a subject via non-invasive spectrographic 
analysis of certain regions of the eye, such as the aqueous 
humor in the anterior chamber of the eye. 
BACKGROUND OF THE INVENTION 
Non-invasive measurement of physiological and foreign 
substances, including blood glucose, by optical spectros- 
copy techniques has remained an elusive target for at least 
two decades. Blood, tissue, and most excreted fluids contain 
numerous substances which confound many spectral signa- 
tures. On the other hand, the aqueous humor (AH), which 
fills the anterior chamber of the eye (between the lens and 
cornea), contains relatively few molecules capable of inter- 
fering with the spectroscopic detection of glucose. These are 
primarily lactate, ascorbate, and urea. This fact, along with 
its optically accessible location behind the cornea, makes the 
AH an attractive choice as a site on which to attempt 
non-invasive analysis of many substances present in a 
biological subject, including glucose. 
Pohjola (Acta Ophthalmologica Suppl. 88, 1-80 (1996)) 
showed that the ratio of aqueous glucose to plasma glucose 
in normal euglycemic individuals is related to age and 
ranges from 0.6 to 0.9. He further showed in seven humans 
with steady-state hyperglycemia that similar ratios applied. 
There is little, if any, data regarding the equilibration time of 
aqueous humor glucose with changes in plasma glucose in 
humans. Some recent research suggests that the glucose 
content of the AH compared with that in the capillary blood 
in man is about 0.75 regardless of the glycemic state of the 
person. See e.g., Schrader et al., The glucose content of the 
aqueous humour compared with capillary blood in man, 
Invest. Ophthalmol. Vis. Sci. (Suppl.) 44:404 (2000). 
Numerous investigators over the years have suggested 
that the ratio of aqueous glucose to plasma glucose in the 
normoglycemic rabbit ranges from 0.42 to 1.01 (S. Pohjola, 
supra; D. Reddy and V. Kinsey, Arch. Ophthalmol. 63, 
715-720 (1960); M. Reim et al., Ophthalmologica 154, 
39-50 (1967); W. March et al., Diabetes Care 5, 259 
(1982)). It is uncertain whether this variability is normal or 
could be attributed to differences in glucose measurement 
techniques, collection techniques, sample storage, and anes- 
thesia. It is believed that the relationship of aqueous glucose 
to rising, or falling, plasma glucose has not been previously 
studied in rabbits. 
Cot6 has reviewed the relative strengths and weaknesses 
of optical glucose sensing techniques (J. Clin. Engineering 
2 
22, 253 (1997)). Raman spectroscopy is potentially attrac- 
tive because it can distinguish glucose in water solutions 
containing various levels of other optically active metabo- 
lites (S. Wang et al.,Applied Optics 32,925 (1993)). Raman 
5 spectroscopy measures the shift in the wavelength of inci- 
dent light as it is scattered by molecules. Any given mol- 
ecule typically causes a characteristic shift in the spectrum 
of scattered light, which is dependent upon its intermolecu- 
lar and intramolecular bonds. This is in contradistinction to 
fluorescence, which is caused by changes in electron energy 
states, and does not shift relative to the wavelength of 
incident light. 
Wicksted et al, (Appl. Sectroscop. 49,987 (1995)) suggest 
that the Raman signature for glucose can be identified in 
15 aqueous humor samples, and Goetz et al. (ZEEE Tram. 
Biomed. Eng. 42,728 (1995)) have demonstrated that higher 
than physiologic levels of glucose can be measured with 
Raman spectroscopy in water solutions. J. Lambert et al. 
(LEOS Newsletter 12, 19-22 (1998)) suggest that measure- 
2o ment of glucose at physiologic levels is possible in water 
solutions containing other analytes normally found in the 
aqueous humor. In certain situations, when solutions con- 
taining fluorescent substances are studied, however, the 
fluorescence signal may overwhelm the relatively weak 
25 Raman-shifted signal. This is a potential problem if Raman 
spectroscopy is applied to certain regions in the eye, such as 
the conjunctiva or vitreous or aqueous humor (and/or 
depending upon what the Raman signal is attempting to 
identify or measurer), which can contain proteins that fluo- 
U.S. Pat. No. 5,243,983 to Tarr et al. proposes a non- 
invasive blood glucose measurement system using stimu- 
lated Raman spectroscopy. Stimulated Raman spectroscopy 
can require the use of both a pump and a probe laser beam. 
35 In operation, the probe laser beam is used to measure the 
stimulated Raman light at a single wavelength after trans- 
mission across the anterior chamber of the eye. 
Commercially, this may be undesirable, since an optical 
component contacting the eye is used to direct the beam 
4o across the anterior chamber. In addition, use of a single 
wavelength may limit the ability to measure glucose at 
physiologic levels within tissue containing many other 
Raman scattering chemicals. 
Others have also proposed various glucose measurement 
45 devices. For example, U.S. Pat. No. 5,433,197 to Stark 
suggests a non-invasive glucose measurement apparatus that 
employs broadband, infrared light stimulation. In addition, 
U.S. Pat. No. 5,553,617 to Barkenhagen proposes a non- 
invasive method for measuring body chemistry from the eye 
50 of a subject by measuring a spectral response such as a 
Raman scattering response. While the latter reference 
alleges that it may be used for medical applications (such as 
the determination of sugar in diabetics), specific details on 
how this might be accurately carried out are not provided. 
5s Another example is found in U.S. Pat. No. 5,710,30 to 
Essenpreis, which proposes a method for measuring the 
concentration of glucose in a biological sample such as the 
eye (see FIG. 4 therein) with interferometric measurement 
procedures. Still another example is proposed in U.S. Pat. 
60 No. 5,666,956 to Buchert et al., wherein it is proposed that 
an instrument for the non-invasive measurement of a body 
analyte can be based on naturally emitted infrared radiation. 
In spite of the foregoing efforts, a commercially viable, 
non-invasive monitor which can successfully employ a 
65 non-invasive optical analysis of certain regions of the eye, 
including the aqueous humor of the eye, has not yet been 
developed. Difficulties in developing such a device include: 
3o resce. 
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(a) determining reliable correlations of the typical millimo- 
lar quantities of selected substances or chemicals; (b) obtain- 
ing accurate measurements of selected substances; and (c) 
inhibiting damaging effects to the eye which may be caused 
by excessive exposure to light in an instrument that is used 
to generate the analysis signal spectrum in the AH. 
Accordingly, there is a continued need for improved 
systems, methods, and devices for the non-invasive in vivo 
analysis of foreign and natural physiologic substances in a 
biological subject via analysis of certain regions of the eye. 
SUMMARY OF THE INVENTION 
The present invention provides methods and systems for 
monitoring or evaluating the blood aqueous barrier and, 
thus, the blood brain barrier dynamics of the subject. The 
present invention also provides methods and systems which 
can detect the presence or absence of one or more selected 
substances or analytes of interest in the body by optically 
analyzing certain regions of the eye, including at least one 
of the AH, the vitreous humor (“VH’)), and one or more 
blood vessels in the conjunctiva. In certain embodiments, 
the analysis can provide information regarding the presence 
of and/or quantify a detected substance in the body such as 
in the cerebral spinal or intracranial fluid of the subject 
(indirectly, through a correlation with the presence or quan- 
tification of the substance in the blood vessel in the 
conjunctiva, or the AH or the vitreous humor). 
Embodiments of the invention can employ Raman spec- 
troscopy to non-invasively obtain, in vivo, at least one 
signature spectroscopic signal to identify and/or measure the 
level or concentration of a substance or substances of 
interest in the subject (either in the blood and/or brain) based 
on the signal. 
In certain embodiments, the present invention can be used 
to monitor or evaluate the blood brain barrier dynamics, 
which may be intentionally altered (such as through the 
administration of chemicals or exposure to certain environ- 
mental conditions such as increased pressure) during such 
evaluation. By intentionally breaking down the blood brain 
barrier, medicines which are normally inhibited from cross- 
ing the barrier may be allowed to more readily cross and 
enter into the brain. To monitor such a change in the 
operation or dynamics of the blood brain barrier, nonspecific 
markers can be introduced or injected into the subject. The 
non-specific marker is selected based on its molecular size 
and/or its normal reluctance to cross the blood brain barrier. 
The blood brain barrier can then be intentionally altered 
(broken down or opened) so that the non-specific marker is 
able to cross therethrough. An optical reading of a selected 
region of the eye can be taken, and the present invention can 
assess whether the marker is present (either at all or in an 
increased amount over a pre-alteration state) in the blood 
aqueous barrier. Further, in some embodiments, the concen- 
tration of the marker in the eye can be determined (such as 
in the AH or vitreous humor) in the blood aqueous com- 
partment. If the marker is identified as being present, this 
indicates that the blood brain barrier has been altered. Once 
the blood brain barrier is altered, a desired treatment regi- 
men can be administered to the subject (such as drug used 
for chemotherapy) to treat tumors or other conditions in the 
eyes or brain. In some embodiments, as an alternative to the 
use of non-specific markers, the present invention can moni- 
tor the presence or concentration of the treatment drug itself 
in the blood aqueous compartment in the eye. Examples of 
suitable markers include large molecule natural and syn- 
thetic substances that do not normally cross the blood brain 
barrier, including, but not limited to, antibiotics including 
4 
antifungal agents and/or erythromycin, and conjugated sub- 
stances such as conjugated billirubin. 
Typically, the treatment drug is configured such that it is 
inhibited from crossing the blood brain barrier. Thus, in 
5 certain applications, in order to deliver a sufficient quantity 
of the drug to the brain, the amount of drug, which is 
systemically delivered, can be undesirably toxic to the 
patient away from the targeted treatment region in the brain. 
The present invention can now assess or assure either that 
10 the barrier is sufficiently altered to allow the drug to pass 
more efficiently therethrough and/or quantify or assess that 
a sufficient amount of the treatment drug is getting into the 
brain so that the systemic amount can be more closely 
regulated and reduced. After the desired treatment (or dose) 
15 is indicated as delivered to the brain, the blood brain barrier 
can be restored such that it is substantially in its pre-altered 
state. The return to the pre-altered state can be confirmed by 
taking another optical reading to confirm that the marker is 
in a reduced concentration in the blood aqueous compart- 
By identifying and/or quantifying the amount of the 
non-specific marker present in the aqueous humor (and, thus 
in the blood aqueous barrier), an estimate or determination 
of the concentration in the brain can be established. 
25 Typically, the concentration in the blood aqueous humor can 
be presumed to be similar to that in the blood brain com- 
partment. Further, the two concentrations can be correlated 
so that a quantitative value of the amount in the cerebral 
spinal or intracranial fluid can be determined based on that 
30 found in the blood aqueous compartment so that a titrated 
dose of the treatment drug in the brain may be able to be 
determined. The correlation relationship or ratio may vary 
within certain population segments. In certain embodiments, 
the correlation relationship can be determined based on data 
35 collected across a representative population (by age, size, 
weight, gender, race, disease or physiological impairment or 
abnormality, or national origin). Thus, the amount of the 
selected treatment drug actually getting into the brain can be 
correlated to the systemic dose delivered to the patient so 
40 that the dose or level in the spinal fluid is sufficiently high 
for treatment of the tumor or other condition but the sys- 
temic dose is sized to provide reduced toxicity to the subject 
(by avoiding administering unnecessary quantities to the 
subject). 
In certain embodiments, the present invention can provide 
methods, similar to that discussed for intentionally altering 
the dynamics of the blood brain barrier, which use a non- 
specific marker with a new drug to evaluate the impact that 
a new drug or therapy regimen has on the blood brain barrier 
for safety or other considerations. 
In other embodiments, the optical detection of an analyte, 
agent, or drug itself, in certain regions of the eye, without the 
use of a marker, may be sufficient to indicate the drug’s 
In other embodiments, the environmental conditions sur- 
rounding the patient or subject, can be altered and the 
dynamics of the blood brain barrier monitored. For example, 
subjects which are exposed to different elevations, gravity 
60 conditions, or to increased intracranial pressure, may exhibit 
different or altered blood brain barrier characteristics, either 
transiently, or more chronically, than persons not so 
exposed. These subjects may include astronauts, pilots, 
divers, trauma victims, and the like. Evaluating the blood 
65 brain barrier dynamics can identify whether larger mol- 
ecules or pathogens are able to cross the blood brain barrier, 
which may, under normal circumstances, be inhibited or 
20 ment in the eye. 
4s 
55 impact on the blood brain barrier. 
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prevented from entering the brain. In certain embodiments, 
the present invention can be used to assess which constitu- 
ents in the blood cross into the intracranial fluid via the 
blood brain barrier. 
As generally described above, in one embodiment, a 
patient can undergo a treatment regimen to deliberately or 
intentionally alter the blood brain barrier dynamics so that 
an identified treatment agent(s) is allowed to cross the 
barrier. For example, an osmotic agent such as a drug (for 
example, MANNITOL) can be delivered to a subject being 
treated for cancer to force the blood brain barrier to open 
(preferably for a limited-time treatment window) to success- 
fully allow a selected chemotherapeutic agent (such as a 
cytotoxic agent) to be able to more readily cross the blood 
brain barrier into the brain. Non-invasive monitoring of the 
tumor dose according to the present invention, can allow 
monitoring of the barrier dynamics and may, in some 
embodiments, be able to assess when an adequate, but not 
excessive, tumor dose is delivered to the brain. The blood 
brain barrier can be reestablished after the appropriate tumor 
dosing is delivered. This monitoring of the blood brain 
barrier dynamics during a treatment regimen may now 
inhibit or reduce systemic damage in the subject associated 
with the cytotoxic treatment. 
In other embodiments, the present invention provides 
systems and methods for detecting the presence of a prede- 
termined substance or identifying the presence of an 
unknown substance in the body of a subject. The substances 
which can be measured or identified are numerous and can 
be (a) natural physiologic analytes or chemicals, such as 
glucose, amino acids, peptides, antibodies, blood (typically 
using light outside the red spectrum), and/or (b) foreign 
substances such as medicaments, drugs, or poisons (whether 
legal or illegal, and whether prescription or over the 
counter). For example, the present invention can be used to 
assess the presence of targeted illegal substances, such as 
alcohol or illegal narcotics such as cocaine, pcp, marijuana, 
or to identify what toxin or poison a subject has injested out 
of a number of household or environmental toxins and/or 
poisons such as herbicides, pesticides, household cleaning 
products, petroleum products or other common house hold 
chemicals including benzene, ethylene glycol. The methods 
and systems of the instant invention may even be used to 
identify the presence of poisonous plants, insect toxins, and 
reptile or snake venom. The present invention may be 
configured to identify whether an unknown substance in a 
subject is one or more of toxins/agents associated with the 
most prevalent poison-related emergency room visits. For 
example, ethylene glycol, methanol, and acetaminophen. 
In certain embodiments, the present invention can be used 
to quantify the amount of a substance in the subject. Typi- 
cally this embodiment may be particularly suitable for those 
substances ingested or existing in relatively large quantities 
or those present in sufficient quantity in the selected region 
of the eye so as to be detectable in vivo, or so that the 
substance or analyte is present in physiological levels (in the 
blood or blood aqueous compartment) of above about 
0.001% or above about 0.01-10 pmolars. In certain 
embodiments, the system and methods can assess low levels 
of analytes, such as between nano-micromolar levels, 
depending on the Raman active characteristics of the analyte 
of interest. For example, for certain substances having 
molecules that generate resonant Raman spectra and, the 
signal strength can be greatly enhanced for certain excitation 
wavelengths that, in turn, may reduce the amount of the 
analyte that is detectable over non-resonant Raman spectra 
at that wavelength. 
6 
In addition, in certain embodiments, the devices and 
methods of the present invention may be used to detect 
increased or decreased levels of physiologic analytes such as 
caused by system impairments or reactions associated with 
s dehydration, allergic reactions, or physiologic analytes asso- 
ciated with bacterial infections such as spinal meningitis, or 
to identify whether proteins or antibodies are present in 
elevated levels to identify a systemic response or a localized 
infection or disease in the eye or an immune system 
i o  response, in the subject. Certain particular embodiments of 
the invention may also be used to treat the eye. 
In certain embodiments, the systems and methods of the 
present invention may be able to detect or identify toxins 
released or emitted from foods contaminated with food 
15 poisoning bacteria such as E coli, salmonella (either in vivo 
or in vitro). Further, in some embodiments, the methods and 
systems of the present invent may be used to identify the 
presence of mad cow disease by analyzing certain regions of 
the eye (either in vitro or in vivo) such as by obtaining a 
20 Raman spectrum of a desired region of the eye analyzing the 
spectrum to detect the presence of small peptides or other 
markers associated with the disease. Other diseases may be 
able to be identified in vivo by the presence of a systemic 
reaction (such as an increased constituent level of a natural 
25 physiologic substance) in the subject. It is anticipated that 
such a method may be potentially used to assess whether the 
subject has contracted Lyme disease associated with deer 
tick bites or Rocky Mountain spotted fever. 
In some embodiments, the invention can identify the 
30 presence of one or a plurality of household or environmental 
poisons in the subject in a relatively fast “triage” assessment 
to allow clinicians to determine the appropriate treatment in 
a timely manner. This can be particularly important for 
pediatric applications where the substance ingested may be 
35 difficult to ascertain for young children, and a relatively 
quick identification of a particular toxin or toxins ingested 
may allow more reliable or faster treatment decisions to be 
established. 
One embodiment of the invention is directed to an in vivo 
method for monitoring the blood brain barrier dynamics of 
a subject, comprising the step of monitoring the dynamics of 
the blood brain barrier by non-invasively obtaining the 
Raman spectrum of a selected region in the eye of the 
45 subject. The method may also include the step administering 
a non-specific marker to the subject selected for its normal 
reluctance to cross the blood brain barrier under the normal 
condition. The monitoring step can comprise detecting the 
presence of the non-specific marker in the selected region of 
the eye of the subject. 
In certain embodiments, the method can include the steps 
of  altering the dynamics of the blood brain barrier of the 
subject from a normal condition; and administering a quan- 
tity of a selected therapeutic agent to a subject for treatment 
55 of condition in the brain or neurological system after the 
altering step. It can also include the step of substantially 
returning the blood brain barrier to its normal state after a 
sufficient quantity of the therapeutic agent has been deliv- 
ered to the brain. Similarly, the monitoring step can be 
60 performed before the therapeutic drug is administered to the 
subject and subsequently to confirm that the blood brain 
barrier is substantially returned to its normal condition. The 
method may also include the step of assessing the dose 
amount of the therapeutic agent delivered to the brain. 
Certain embodiments of the present invention are directed 
to an in vivo a non-invasive method for determining the 
level of an analyte of interest in a biological subject. Raman 
4o 
65 
US 6,9( 
7 
spectroscopy can be used to obtain the signature of the 
substance in the eye (such as in the AH, VH, or blood vessel 
in the conjunctiva) and, in some embodiments, to measure 
the concentration of a natural physiologic or foreign 
substance, such as glucose and/or proteins, or drugs, alcohol, 
environmental or household toxins, in the subject. The 
method can include the steps of  (a) generating an excitation 
laser beam (e.g., at a wavelength of from about 400 to 900 
nanometers); (b) focusing the excitation laser beam into the 
eye of the subject so that a selected region of the eye is 
illuminated; (c) detecting (preferably confocally detecting) a 
Raman spectrum from the illuminated region of the eye; (d) 
comparing the Raman spectrum from the detecting step to 
predetermined spectrums corresponding to different analytes 
of different concentrations; and (e) identifying the presence 
of an analyte of interest based on the detecting and com- 
paring steps. 
In some embodiments, an additional step ( f )  can be 
performed to determine the blood or brain level of an analyte 
of interest for the subject from the Raman spectrum. The 
blood or brain level may be indirectly computated based on 
the concentration or amount of the analyte in the blood 
aqueous compartment (or can be directly measured in the 
blood itself for the conjunctiva vessel measurement). For the 
indirect measurement, that value can be correlated (or 
adjusted/corrected) to provide an assessment of the amount 
of the substance in the cerebral spinal fluid or blood. The 
correlation may be such that the amount of the substance 
directly measured in the AH is substantially similar to that 
in the cerebral spinal fluid. Alternatively, data correlating the 
relationship can be established and an empirical or statistical 
model established. 
Although not required, in some embodiments, the detect- 
ing step can be followed by the step of subtracting a 
confounding fluorescence spectrum from the Raman spec- 
trum to produce a difference spectrum; and determining the 
blood level of the analyte of interest for the subject from that 
difference spectrum, preferably using linear or nonlinear 
multivariate analysis such as partial least squares or artificial 
neural network algorithms. This technique may be particu- 
larly suitable where fluorescence is problematic for optical 
measurements taken directly of the blood level (i.e., by 
focusing at the blood vessels in the conjunctiva or at the 
vitreous humor). 
In certain embodiments, a low energy excitation wave can 
be used to generate the Raman signal spectrum. “Low 
energy”, as used herein, means power which is on the order 
of about 1 0 4 0 0  mJ or less, and typically between about 
70-330 mJ. The energy exposure will depend on the power 
and pulse length of the excitation pulse. Longer wavelength 
pulses (i.e., above 700) may be used, typically with energy 
levels closer to the higher end of the scale, while lower 
wavelengths (400-700) may be used with lower energy 
exposure levels. In one embodiment, a wavelength of about 
633 nm can be used for a pulse of about 5-10 seconds 
corresponding to about a 2-5 mW power exposure level (and 
between a 10-20 or 25-50 mJ energy exposure to the 
patient’s eye (or eyes)) for each measurement or monitoring 
signal obtained. In other embodiments, an optical excitation 
pulse may have a 785 nm wavelength, a pulse length of 
about 20 ms-5 s and a power rating of about 14-16 mW. In 
one embodiment, a 5 sec, 16 mW pulse can be used to obtain 
the in vivo reading of a cancer agent in the selected region 
of the eye (typically the AH). In yet other embodiments, for 
detecting and/or quantifying the presence of substances 
comprising particular molecules, an excitation wavelength 
can be selected that substantially corresponds to the absorp- 
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tion spectrum wavelength (for predetermined molecules that 
generate resonant Raman) with a reduced power require- 
ment of between about 1-5 mW and an exposure time of 
about 10 seconds or less. 
In some embodiments, the excitation beam can be trans- 
mitted such that it presents a reduced energyidensity expo- 
sure rating to the tissue of the eye by shaping the beam to 
increase the cone angle or span of the excitation beam as it 
enters the eye to expose more of the area of the retina and 
reduce the energyiarea rating of the excitation pulse to 
provide improved margins of safety (placing the energyiarea 
rating sufficiently below the threshold of damage). In other 
embodiments, the transmission path numerical aperture is 
substantially matched to the return path numerical aperture 
(of the spectrometer). 
A second aspect of the present invention is an apparatus 
for the non-invasive in vivo determination of the blood level 
of an analyte of interest in a subject. The apparatus includes 
a laser source for generating an excitation laser beam (e.g., 
at a wavelength of from about 400 to 900 nanometers) and 
an optical system (e.g., a confocal optical system) opera- 
tively associated with the laser for focusing the excitation 
laser beam into a selected region of the eye, including one 
or more blood vessels in the conjunctiva of the eye, the 
vitreous humor, or the anterior chamber of an eye (or eyes) 
of the subject so that the aqueous humor in the desired 
region of the eye is sufficiently illuminated. The apparatus 
also includes a detector operatively associated with the 
optical system and configured to detect a Raman spectrum 
from the selected illuminated region of the eye and a 
processor with computer program code for identifying the 
presence of one or more selected substances or analytes of 
interest. The computer code may also include code for 
determining the in vivo level of the analyte of interest in the 
selected region of the eye and to establish an estimate or 
measure of the analyte in the blood or cerebral spinal fluid 
to be established based on a correlation thereto for the 
subject from the Raman spectrum. 
Focusing the optical analysis on the blood vessels in the 
conjunctiva can allow for a direct measurement of the 
substance in the blood, while the measurements taken from 
other portions of the eye can be correlated to provide an 
estimate or quantification of the substance in the blood 
and/or in the cerebral spinal fluid (i.e., indirect 
measurements). The correlation’s can be established based 
on empirical models or actual measurements taken in vitro 
or in vivo on a representative animal or human population as 
is well known to those of skill in the art. 
In certain embodiments, the apparatus can be configured 
as a low energy unit to inhibit the exposure of the tissue 
during the operation of the apparatus. The excitation wave- 
length at the low power may be less than 700 nm, such as 
about 406 nm or 633 nm. 
Numerous additional features may be incorporated into 
the apparatus. The device may include a visual display 
screen for presenting visual indicia to the user, which can be 
individually adjusted and focused to the particular visual 
acuity of the subject (similar to vision screening focusing 
procedures). The apparatus may include a visual display 
screen for visually displaying the results of the test to the 
subject (such as through the same aperture or adjacent active 
matrix screen) as which the test is conducted. It may include 
a visual fixation target or device, also visible through the test 
aperture, which controls movement of the eye and simulta- 
neously insures that focusing of the laser beam is properly 
directed into the anterior chamber of the eye. The processor 
US 6,961,599 B2 
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may contain empirical models of actual testing experience to pated that the correlation between the blood-aqueous and 
either determine the blood level or concentration of the blood brain barrier is such that the presence and/or concen- 
analyte of interest or to identify the presence of selected tration in one can be extrapolated to that in the other. 
substances. The apparatus may employ a laser of fixed Other embodiments focus the excitation beam such that it 
wavelength, a tunable laser (which can sample a plurality of 5 has an increased or wider cone angle to spread the light 
Raman scattered light (at different wavelengths) across more area of the retina. Still other embodiments are 
concurrently), a plurality of fixed wavelength lasers, or other configured to focus to one or more blood vessels on the 
light source means some of which can include means for 
sliding the Raman spectrum Passed a Plurality of different In certain embodiments, the monitoring step can be used 
wavelength detectors to obviate the need for a full grating 10 to assess whether the dynamics thereof alter sufficiently to 
based Raman taking a Plurality Of allow selected analytes, which would normally be inhibited 
The a wireless Or remote from traveling through the blood brain barrier, to pass into 
communication line operably associated with the processor the intracranial spinal fluid through the blood brain barrier, 
for transmitting the blood level of the analyte of interest to other embodiments, the monitoring step can be carried out 
a remote location (such as for emergency home calls to an 1s when a person is under or exposed to extreme conditions 
ER room). such as when diving, flying, or mountain climbing, or when 
Other devices may be particularly configured to detect the suffering from a traumatic head or brain injury, or high 
presence of a selected substance and thus, configured to stress, and the like. 
detect the ensemble Profile of the spectrum Or a Peak Or The method can also include the steps of comparing the 
peaks of interest. Acompact, inexpensive device can include 20 R~~~~ spectrum from the detecting step to reference spec- 
a fixed wavelength diode laser excitation source (configured trums corresponding to at least one selected analyte of 
to operate SO as to generate a resonant Raman spectrum for interest; and identifying the presence of the least one analyte 
a molecule of interest), and a filter, a lens, and detector. of interest in the subject based on the detecting and com- 
Another aspect of the present invention is an in vivo paring steps in the selected region of the eye. The method 
method for administering drug or chemical therapy to a 2s may also be able to estimate the dose or affirm the presence 
subject (such as for treatment of a cancerous tumor in the of the analyte in the subject’s cerebral spinal fluid. 
brain). The method includes the steps of  (a) administering Other embodiments are directed to non-invasive methods 
a dose of a selected therapeutic agent to a subject; (b) for identifying the presence of and/or the concentration of a 
conjunctiva or to focus deeper to the vitreous humor. 
altering the dynamics of the blood brain barrier from its selected analyte in a subject, The methods include: illumi- 
normal state; (c) monitoring the dynamics of the blood brain 30 nating a selected region of the eye with an optical excitation 
barrier by non-invasively obtaining the Raman spectrum of beam, wherein the excitation beam wavelength is selected to 
a selected region in the eye (such as the vitreous Or aqueous generate a resonant Raman spectrum of the selected analyte 
humor) and determining the quantity of the agent therein. with a signal strength that is at least 100 times greater than 
The method may also include one Or more of (d) estimating Raman spectrums generated by non-resonant wavelengths 
the dose of the therapeutic agent delivered to the brain 3s and/or relative to signals of normal constituents present in 
(indirectly, based on the amount detected in the selected the selected region of the eye; detecting a resonant Raman 
region of the eye) (e) repeating said monitoring step a spectrum corresponding to the selected illuminated region of 
Plurality of times during the administering step; and ( f )  the eye; and identifying the presence and/or the concentra- 
returning the blood brain barrier to its normal state after a 4o tion of the selected analyte in the subject based on the 
sufficient quantity of agent has been delivered to the brain. detecting step. 
In one embodiment, the altering step can be carried out by Still other embodiments are directed to operations 
introducing a chemical to the subject to temporarily open the (methods or apparatus) that can determine the presence of 
blood brain barrier to allow larger molecules to pass there- and/or the concentration of a selected analyte in a subject 
through. Further, the method can include the step of admin- 4s and identify the subject. The operations can include: (a) 
istering a non-specific marker which is reluctant to or does illuminating a selected region of the eye of a subject with an 
not normally pass through the blood brain barrier (i.e., is optical excitation beam; (b) detecting a response spectrum 
typically inhibited from passing therethrough). The optical corresponding to the selected illuminated region of the eye; 
analysis can monitor any increase (or the presence) of the (c) determining the presence, absence and/or the concentra- 
non-specific marker in the selected region of the eye to tion of the selected analyte in the subject based on the 
confirm that the blood brain barrier dynamics has been detecting step; and (d) obtaining a biometric reading of the 
altered. iris or retinal structure to identify the subject based on the 
In another embodiment, the altering step may be carried biometric reading. 
out by increasing the intracranial pressure of the subject. In certain embodiments, the obtaining step can be carried 
Another aspect of the present invention is a method of ss out by obtaining an image of the iris and comparing the 
non-invasively monitoring the blood brain barrier. The image to predetermined iris characteristics of that subject. 
method comprises the steps of (a) generating an excitation The detected spectrum can be, but is not required to be, a 
beam at a wavelength of from 400 to 900 nanometers; (b) Raman spectrum. 
focusing the excitation beam of said generating step into the Each of the embodiments of the invention may include 
anterior chamber of an eye of the subject so that aqueous 60 computer program products (or computer code that imple- 
humor in the anterior chamber is illuminated; (c) detecting ments certain operations) and/or computational and look-up 
a Raman spectrum corresponding to the illuminated aqueous tables associated therewith to identify the presence of the 
humor; and (d) monitoring the AH to predict the behavior of selected substance or substances of interest (and/or calculate 
the blood brain barrier dynamics during exposure to selected the amount or concentration thereof) and to operate or 
conditions based on the detecting step (based on the AH 65 control (regulate) the power of the excitation pulse emitted 
Raman spectrum analysis’ indication of the presence or from the laser, and the illumination and detection of the 
concentration of selected substances therein). It is antici- scattered light. 
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For example, in certain embodiments, the present inven- 
tion can include a computer program product for determin- 
ing the identity of an unknown substance in a subject. The 
product can comprise computer-readable program code 
comprising: (a) computer readable program code for defin- 
ing at least one signature reference spectrum for at least one 
selected substance of interest; (b) computer readable pro- 
gram code for analyzing an in vivo obtained Raman spec- 
trum of the aqueous humor of the subject; and (c) computer 
readable program code for based evaluating whether the in 
vivo Raman spectrum corresponds to at least one of the at 
lest one signature reference spectrums by comparing 
selected characteristics between the reference spectrum and 
the in vivo spectrum. 
In various embodiments, the computer readable program 
code for defining the different reference spectrums can be for 
a particular one or a plurality of different selected sub- 
stances. Examples of the selected substance(s) include, but 
are not limited to: drugs or analytes of interest including, but 
not limited to, alcohol, a substance banned for athletes in 
competition, a plurality of illegal narcotic substances, a 
plurality of household products or common poisons for 
humans or animals which are potentially poisonous to a 
subject when ingested, a chemotherapy agent, an antifungal 
agent, antibiotics, naturally occurring in vivo analytes, and 
the like. A master look-up reference data base providing 
Raman spectrum data for one or a large quantity of different 
poisons or substances can be generated and stored at a 
central database or at local or regional offices, clinics or the 
like. The computer program can include means for remotely 
accessing the data such as via the use of an intranet or 
Internet. 
Other embodiments are directed to a non-invasive method 
for identifying the presence of and/or the quantity of a 
selected analyte in a subject. The methods include: (a) 
providing an excitation beam at a wavelength that is selected 
to generate a resonant Raman spectrum of the selected 
analyte with a signal strength that is at least 100 times 
greater than Raman spectrums generated by excitation 
wavelengths that are not resonant or strongly pre-resonant; 
(b) focusing the excitation beam of said generating step into 
a selected region in the eye of the subject so that the selected 
region is illuminated; (c) detecting a Raman spectrum cor- 
responding to the illuminated selected region; and (d) iden- 
tifying the presence of and/or the quantity of the selected 
analyte in the subject based on said detecting and comparing 
steps. 
The wavelength can be between about 400 nm-900 nm. 
The selected analyte can be a chemotherapeutic agent, an 
antifungal agent, or other analyte of interest. The method 
may also include monitoring at least one peak of interest in 
the detected Raman spectrum associated with a carbon- 
carbon bond and/or a double carbon bond associated with 
the chemical structure of the selected analyte. 
In particular embodiments, the selected analyte comprises 
fenretinide or its substantial chemical equivalent and the 
excitation wavelength may be between about 40Ck514 nm. 
In other embodiments, the selected analyte comprises 
amphotecin B or its substantial chemical equivalent and the 
excitation wavelength may also between about 400-514 nm. 
Other analytes may be resonant (or strongly pre or post- 
resonant) at other excitation wavelength ranges. 
Still other embodiments are directed to methods of moni- 
toring ethanol and/or its constituents in a subject using 
Raman spectroscopy. The methods include: (a) obtaining a 
plurality of reference Raman spectrums of varying concen- 
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trations of ethanol and/or its metabolites; (b) transmitting an 
excitation beam at a wavelength of from 400 to 900 nanom- 
eters to an eye of a subject; (c) obtaining a Raman spectrum 
of ethanol and/or its metabolites in the eye of the subject; (d) 
comparing the Raman spectrum from said obtaining step to 
at least one of the reference spectrums; and (e) determining 
the presence of and/or the concentration of the ethanol 
and/or its metabolites in the subject based on said obtaining 
and comparing steps. 
The transmitting step may be carried out by confocally 
delivering the excitation beam to the aqueous humor of the 
eye of the subject. 
The present invention will now be described further and 
includes other features and analytes that can be included in 
the methods and apparatus described herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph which illustrates the broad spectrum of 
water in the aqueous humor, which, in some situations, can 
obscure the underlying peaks of interest in the Raman 
spectrum. The raw spectrum of rabbit aqueous humor is 
shown taken at 2 slightly different wavelengths (top). The 
difference spectrum (bottom) achieved by subtracting 1 raw 
spectrum from the other reveals a resultant bipolar Raman 
signature. Linear and/or nonlinear multivariate analysis can 
then be applied. 
FIG. 2 is a graph plotting Raman predicted glucose as a 
function of actual glucose concentration. The glucose con- 
centration in aqueous humor from 16 rabbits was estimated 
with Raman spectroscopy and compared to the actual glu- 
cose concentration measured with a commercial glucometer. 
The graph shows the Raman predicted glucose concentration 
after subtracting fluorescence and applying a linear partial 
least square algorithm followed by nonlinear back propaga- 
tion with an artificial neural network. This resulted in a high 
degree of correlation (r2=0.98) of predicted with actual 
glucose concentration. Applying the partial least squares 
algorithm alone resulted in lesser correlation (r2=0.90). 
FIG. 3 is a graph plotting blood glucose as a function of 
time. Blood glucose steadily rises at variable rates in rabbits 
after administration of xylazine anesthesia. One animal 
(rabbit D, filled diamonds) had little change in blood glucose 
for unknown reasons. 
FIG. 4 is a graph plotting aqueous humor glucose as a 
function of blood glucose. Best-fit second-order polynomial 
curves demonstrate the relationship between aqueous humor 
glucose and plasma glucose while plasma glucose is rising 
in 9 animals. Aqueous glucose measurements from the first 
paracentesis of an eye correlate well with simultaneous 
plasma glucose (dark curve). When plasma glucose exceeds 
200 mgidL the relationship is nearly linear (dashed line). 
Aqueous humor glucose exceeds plasma glucose when 
plasma glucose is less than 200 mg/dL. The relationship of 
aqueous humor glucose with plasma glucose is different 
when the aqueous humor sample is obtained as a second 
paracentesis (light curve) suggesting that the initial para- 
centesis disrupts normal glucose homeostasis. 
FIG. 5 schematically illustrates a first embodiment of an 
apparatus of the invention. 
FIG. 6 schematically illustrates a second embodiment of 
an apparatus of the invention. 
FIG. 7a  schematically illustrates the method of sliding 
Raman spectra features through a particular detector win- 
dow by changing excitation frequency. 
FIG. 7b schematically illustrates an apparatus of the 
invention that utilizes the method illustrated in FIG. 7a. 
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FIG. 8 illustrates a visual fixation display that can be 
FIG. 9 illustrates a visible readout display that can be 
FIG. 10a is a schematic illustration of one embodiment of 
of actual aqueous humor in a model anterior chamber. FIG. 
21C corresponds to in vivo ensemble spectrum of aqueous 
humor. 
FIG. 22A is a drawing of the chemical structure of a 
5 chemotherapeutic agent known as fenretinide. FIG. 22B 
illustrates the agent in ethanol in different concentrations 
present invention. pM (micro-molars), 10 pM, 1 pM, and 0.1 pM. 
FIG. lob is a schematic illustration of one embodiment of FIG, 23 is a graph of the absorption spectrum (absorption 
a detection system according to the Present invention. versus wavelength) of a solution of 10 pM of fenretinide 
FIG. 1Oc is a schematic of one embodiment of a system illustrating the peak at 365 nm. 
with a closed loop feedback control system according to the FIG. 24 is graph of the Raman spectrum of intensity 
present invention. verses wavelength shift of a non-resonant Raman spectros- 
feedback system according to embodiments of the present 15 tinide (dissolved in ethanol). There are two distinct lines, 
one for ethanol and one for fenretinide that shows key peaks invention. of fenretinide as distinct from those of ethanol. 
FIG. 11 is a block diagram of a method for determining FIG, 2 5 ~  is a graph of the absorption spectrum 
the presence or the blood level concentration of a selected (absorption wavelength) of a solution of 10 m~ of 
analyte according to certain embodiments of the present fenretinide, FIG, 2 5 ~  is inset within FIG, 2513, 
invention. FIG. 25B is a graph of pre-resonant spectra (excitation 
FIG. 12 is a block diagram of a method for identifying the wavelengths above the resonant wavelength) of a 10 mM 
presence of at least one selected substance in a selected fenretinide corresponding to the substance with the absorp- 
region of the eye of a subject to evaluate the quantity of same tion spectrum shown in FIG. 25A. 
in the cerebral spinal or intracranial fluid (it being assumed FIG. 26 is a graph of intensity versus wavelength shift of 
that the mechanics of the blood aqueous barrier can be 25 the resonant Raman (RR) spectra of fenretinide at three 
representative to the blood brain barrier, the same having different concentrations (mixed in ETOH), 10.OpW 1.0pM, 
passed through the blood brain barrier) according to certain and 0.1 PM. The Peaks from the solvent (s), ethanol are 
embodiments of the present invention. diminished at the higher fenretinide concentrations due to 
the absorption of excitation light by the fenretinide itself. 
of amphotericin, an exemplary antifungal agent. 
tericin B. 
utilized in an apparatus of the invention. 
utilized in an apparatus of the invention. 
a light generation Or light pulse system according to the (shown in decreasing concentration from left to right) of 100 
FIG, 10d is a schematic of an alternate closed loop an excitation Of 785 nm> Of fenre- 
20 
FIG. 13 is a block diagram of a method for monitoring or 3o 
treating a patient by administering a therapeutic agent during 27 is a drawing Of the conjugated structure 
a chemotherapy session patient according to embodiments 
of the present invention. FIG. 28 is a graph of the absorption spectrum of ampho- 
l4 is a diagram Of a method Of monitoring the FIG, 29 is a graph of the RR spectrum of (generated at an 
brain barrier dynamics Of a subject during exposure to 35 excitation wavelength of 406.7 nm) of amphotericin at three 
selected conditions according to embodiments of the present 
invention. pgiml, and 0.05 pgiml. 
FIG. 15 is a block diagram of a method for detecting an 
alteration of the function of the blood brain barrier according 
to certain embodiments of the present invention. 
FIG. 16 is a block diagram of a method for identifying an 
abnormality in the blood brain barrier of a subject according 
to embodiments of the present invention. 
embodiment of the present invention. 
FIG. 18 is a schematic illustration of an apparatus con- 
figured to illuminate and obtain the Raman spectrum from 
the vitreous humor of the eye according to embodiments of FIG, 32 is a graph of amplitude (arbitrary units) 
so wave number of normalized Raman spectra of various levels the invention. 
FIG. 19 is a schematic illustration of an apparatus con- of ethanol in artificial aqueous humor according to embodi- 
figured to illuminate and obtain the Raman spectrum of one ments of the present invention, 
or more blood vessels in the conjunctiva of the eye accord- FIG, 33 is a graph of PLS-measured ethanol concentration 
versus actual ethanol concentration in aqueous solution ing to embodiments of the invention. 
tions performed using a canonical model of the adult eye of FIG, 34 is a graph of the R~~~~ spectra for 0 , 3 3 3 ~  
a 20A is a Of the human eye. 20B aqueous solutions of ethanol, acetaldehyde, acetic acid, and 
is a schematic of a portion of the eye illustrating the angles mixed metabolites according to embodiments of the present 
an equations associated with power density. FIG. 20C is a invention, 
density (assuming a 30 mW hut) are shown as a function and/or a data processing system according to embodiments 
of the present invention. of the angle of incidence. 
FIGS. 21A-21C are graphs of the Raman spectrum of 
artificial and actual aqueous humor samples. FIG. 21A 
corresponds to an ensemble spectrum of artificial aqueous 65 
humor samples in a model (artificial or test) anterior cham- 
ber. FIG. 21B corresponds to an in vitro ensemble spectrum 
different concentrations (mixed in M ~ O H ) ,  5.0 pgiml, 0.5 
FIG. 30 is a schematic of a compact portable detector 
suitable for detecting the presence of a particular substance 
40 according to embodiments of the present invention. 
FIGS. 31A and 31B are graphs of intensity (arbitrary 
units) versus wave number of Raman spectrums. FIG. 31A 
is a graph of Raman spectra of an artificial aqueous humor 
and components of a physical model of the anterior chamber 
l7 is a flow chart Of a method according to One 45 collected using confocal optics. FIG. 31B is a graph of 
Raman spectra of structures of the anterior chamber of a 
rabbit, The R~~~~ spectra of can be clearly &tin- 
guished from those of nearby and lens, 
FIGS. 20A-20C illustrate optical power density calcula- 55 according to embodiments of the present invention, 
graph Of the power for exposed area and the power 60 FIG, 35 is a block diagram of a computer program module 
DESCRIPTION OF EMBODIMENTS OF THE 
INVENTION 
The present invention will now be described more fully 
hereinafter with reference to the accompanying figures, in 
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which embodiments of the invention are shown. This inven- concentration of or (b) the movement through or alteration 
tion may, however, be embodied in many different forms and of the blood-brain barrier of a selected or desired substance. 
should not be construed as limited to the embodiments set The substances include lactate, urea, benzene, ascorbate 
forth herein. Like numbers refer to like elements throughout. alcohol, ethanol, methanol, ethylene glycol, steroids, 
In the figures, layers, components, or features may be 5 nicotine, or illegal narcotics such as cocaine, other opiate- 
exaggerated for clarity and broken lines indicate optional based drugs, or prevalent or pervasive designer drugs, or 
features or operations unless described otherwise. metabolites, or household, organic, or environmental toxins 
’& term “glucose” as used herein preferably refers to and/or poisons such as herbicides, pesticides, household 
D-glucose. The term “subject” as used herein refers to both cleaning products, petroleum products, therapeutic agents 
human subjects and animal subjects having circulatory sys- such as chemotherapeutic agents, antifungal or other anti- 
tems including domestic large and small animals such as biotic agents or other chemicals. 
dogs, cats, rabbits, horses, cows, pigs, and the like. Animal In certain embodiments, the present invention may be 
subjects may be used in the present invention for veterinary particularly suitable for identifying the presence or amount 
or pharmaceutical drug study purposes. The present inven- of substances, which present in the selected region of the eye 
tion may be particularly suitable for human subjects. The 1s in sufficient quantities to allow Raman based detection. For 
optical analysis may be performed on selected regions of the example, in certain embodiments, the present invention may 
eye, including the blood vessels in the conjunctiva (i.e., one be able to detect a substance that is present in an amount of 
or more of the conjunctiva blood vessels located on the at least about 0.01-10 pmolars. In other embodiments, the 
surface of the eye), the vitreous humor (the “VH’) or the present invention can detect a substance that is present in at 
aqueous humor (the “AH”). 2o least about 1-100 or 1&100 pmolars. The lower quantities 
In certain embodiments, the present invention is con- may be more reliably detectable if the substance is a Raman 
cerned with the determination of (a) the blood levels or (b) active molecule with enhanced signal strength obtained by 
the brain fluid level, meaning the intracranial or cerebral using an excitation wavelength that approaches the sub- 
spinal fluid levels, of selected substances or analytes of stance or molecule of interests absorption spectrum or RR 
interest such as may be predicted by the presence and/or 2s excitation wavelength. In some embodiments, the targeted 
concentration of the substance or analyte in the selected analyte may be present in the selected or targeted region of 
region of the eye of a subject (typically, the AH or the the eye in an amount of at least about 1 milli-molar or in a 
conjuctiva vessel(s)). physiological concentration level of about at least 0.001%. 
In certain embodiments, the present invention recognizes The Present invention may also be able to identify the 
that the mechanics of the blood aqueous barrier and the 30 Presence of, Or a PhYsiologic reaction to, substances asso- 
blood brain barrier are substantially the same such that, if the ciated with Poisonous Plants, insect Or arachnid Poison, and 
substance of analyte passes through the blood aqueous reptile Or snake venom, in the subject. 
barrier, it can be presumed to also pass through the blood In addition, in certain embodiments, the devices and 
brain barrier. The correlation of the amount that passes methods of the present invention may be used (to analyze 
through the blood brain barrier may be substantially equiva- 35 either in vitro or in vivo) to detect increased or decreased 
lent to that detected in the eye or may be at a lesser or greater levels of physiologic analytes in the blood or to detect 
concentration. However, the blood concentration of other certain disease processes of known conditions and/or to treat 
Raman-active molecules, analytes, or substances which do conditions of the eye. For example, by identifying increased 
not typically pass through the blood brain barrier may also or decreased levels of certain substances in the body or the 
be determined by these techniques. Similarly, the amount or 40 presence in the subject of certain peptides or toxins associ- 
presence of the selected substance or molecule, etc., in the ated with a particular condition, such as those caused by 
eye itself can be determined by these techniques (such as to system impairments or  reactions associated with 
treat localized in the eye or non-systemic diseases such as dehydration, allergic reactions, toxins from bacterial infec- 
cancers of the eye). tions such as spinal meningitis, or elevated or decreased 
used herein, the term “analyte” is used interchange- 45 levels of antibodies to identify an immune system response, 
ably with “substance” to identify a selected target chemical, Or even hormones evoked in response to a Pregnancy. 
molecule or molecules, either in its blood-absorbed or In certain embodiments, the methods and devices of the 
partially absorbed, uptaken, or constituent form, or in an ex present invention can be configured to (a) identify the 
vivo formulation, where applicable. As such, the substance presence of and/or (b) quantitatively estimate or determine 
or analyte can include a chemical compound or composition, 50 the blood and/or cerebral spinal or intracranial concentration 
whether synthetic or natural, as well as a constituent thereof level of one or more selected substances in the subject. The 
or molecule of interest. In Some embodiments, the analyte or quantitative assessment can include determining how much 
substance can be one that is emitted by the body (sometimes of the selected substance is crossing the blood brain barrier 
in an elevated amount) in response to a disease or physi- (based on a correlation to the amount present in the selected 
ologic reaction to a product or toxin and may also be a ss region of the eye, typically the AH). In other embodiments, 
byproduct of the body’s reaction to a substance. As such, as the methods and devices of the invention can be used to 
noted in the summary of the invention above, the substances dynamically monitor changes in the operation of the blood 
which can be measured or identified according to the present brain barrier (which may be altered intentionally for some 
invention are numerous and can include (a) natural physi- embodiments of the invention). 
ologic substances, analytes or chemicals, such as glucose, 60 In any event, generally stated, in operation, a laser exci- 
amino acids, peptides, blood, or other components of or in tation light signal is focused to and transmitted into a 
blood, or in the eye and/or (b) foreign or synthetic or selected region in the eye. Typically, this will be the AH, but, 
artificial substances such as medicaments, drugs, or poisons in some embodiments, can also include either the blood 
(whether legal or illegal, and whether prescription or over vessel(s) in the conjunctiva or the vitreous humor. Illumi- 
the counter) which may be present in the subject. For 65 nation of the blood vessel(s) in the conjunctiva of the eye 
example, the present invention can be used to: (a) identify or will not require as great a penetration depth as either the AH 
assess the presence (or absence) of and/or the blood level or or the vitreous humor, while the vitreous humor will require 
US 6,961,599 B2 
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the excitation light pulse to have an increased penetration 
depth over that of the AH and the conjunctiva to reach the 
vitreous humor in the eye. 
In any event, after the selected region of the eye is 
illuminated, a corresponding Raman spectroscopic signal is 
obtained. Each selected substance can generate a “signature” 
spectrographic signal with different signature peaks at dif- 
ferent frequencies. Higher concentrations will yield stronger 
signals. The subject’s spectroscopic signal can then be 
digitally compared to a plurality of reference signals stored 
in computer memory. The reference signals correspond to 
one or more selected substances which can be predetermined 
from an in vitro analysis of the substance as it exists in a 
corresponding sample.  For example,  for the AH 
measurement, a representative eye AH can be a representa- 
tive target phantom such as in artificial AH’S, or test vials 
with known concentrations of the substance in a known 
solvent, such as a water based or saline solution. 
In certain embodiments, the actual signal of the subject 
can then be compared to the stored “signature” profiles or 
signals of Raman data corresponding to predetermined sub- 
stances or analytes to identify the presence of one or a 
plurality of the selected substances and/or to estimate or 
quantitatively determine the concentration of that 
substance(s) in the subject. Thus, the present invention is 
able to assess, non-invasively, at physiologic levels 
(typically in the millimolar range, but the levels can also be 
in the micromolar range for certain substances), the presence 
of selected substances in the body of the subject. In other 
embodiments, a relative assessment (two or more measure- 
ments of the subject analyzed for differences or changes) 
may be performed, alone, or with the use of base or 
reference spectra. The relative assessment can include 
obtaining at least two different Raman spectrum signals of 
the subject, over time, and comparing any shift in peaks, 
and, thus, physiological changes, in the subject at particular 
frequencies. 
As shown in FIG. 5,  in one embodiment of the present 
invention, the system 5 can be described has having a light 
(excitation or illumination) signal generation portion 8 and 
a detection portion 9 (FIG. lob) with a laser 10 and an 
optical system 1 5 ,  along with a fixation target 25. The 
optical system 15x can be broken into an input portion 15xi 
(relays the light to the subject’s eye) and an output portion 
15x0 (relays the reflected light from the subject). As shown 
in FIG. loa, the light signal generation portion 8 includes the 
laser 10, a signal processor 35s, the input optical system 15xi 
which is configured to direct the light signal into a selected 
region in the eye 12 of the subject (whether the conjunctiva 
vessel(s), the AH, or the vitreous humor). The light genera- 
tion portion 8 shown also includes a fixation target 25 used 
to help focus the subject’s eye to the light transmission path. 
The target 25 may be configured to extend adjacently above, 
below or about the perimeter of a light exit/entrance 
aperture, preferably proximate to the aperture to allow the 
eye to focus directly at or into the aperture during operation 
or data acquisition. 
As shown in FIG. lob, the system 5 also includes the 
detection portion 9 which receives the light as it exits the 
selected region of the eye and detects the Raman spectrum 
associated therewith. The detection portion 9 can include the 
output optical system 15x0 (which may share some of the 
optical components used in the input optical system 15xi), 
and a spectrometer 32s with a detector 32, and a signal 
processor 35s. The signal processor 35s is typically the same 
in the transmission and detection portions 8, 9 of the system 
5 .  
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A schematic diagram of one embodiment of the system 5 
is shown in FIG. 5. In certain embodiments, in operation, a 
tunable, narrow-band laser beam from laser 10 is focused 
into the anterior chamber 11 of the eye 12 through an 
s objective or ocular lens 13 via lens 15 and filter 16, beam 
splitter 17, and filter 20. In certain embodiments, a non- 
fluorescing objective lens with suitable numerical aperture 
(e.g. 0.24.5) can be used such that Raman scattering from 
the selected region (i.e., the aqueous humor) is maximized 
i o  while scattering from adjacent structures (e.g., lens, cornea, 
and iris) is reduced. The objective lens can be configured 
with respect to the eye so that it has adequate working 
distance to permit focusing of the laser into the selected 
region of the eye (for the AH, the middle of the anterior 
is chamber of the eye) without direct contact with or touching 
of the cornea. An integrated fixation target projected from 
display screen 25 can be projected via lens 26 through the 
same objective lens as the laser, but is focused on the retina 
of the eye. Focusing this fixation target on the retina 
20 simultaneously can control direction and focusing of the 
laser light into the desired region of the eye (such as, in some 
embodiments, to the anterior chamber and the AH). 
As shown in FIG. 5,  in certain embodiments, the light 
collected by the objective lens is directed through holo- 
25 graphic notch filters 20,21 to remove the undesired portion 
of the reflected scattered light, such as the Raleigh scattered 
light. The Raman scattered light passes through these filters 
with minimal attenuation and is focused through a confocal 
pinhole aperture 22 by lenses 23, 24. The pinhole and the 
30 focal point in the eye are confocal such that light from 
adjacent structures in the eye can be filtered at this aperture. 
The pinhole 22 also serves as the entrance aperture to the 
spectrometer. The spectrometer shown is an imaging spec- 
trograph with a grating 30, lens 31 and a CCD detector array 
A signal processor 35s, or controller which can be pro- 
vided in a computer 35, controls the laser 10, the fixation 
target and readout display 25, and receives data from the 
CCD detector 32. The architecture of the spectrometer 
40 shown in the figures is merely one example of devices that 
are suitable for this application. Many types of spectro- 
graphs can be utilized including Fourier transform 
spectrographs, spectrographs using liquid crystal tunable 
filters or other tunable elements. Information can be trans- 
45 mitted to a remote source such as a computer, database, 
remote physician or the like via modem or other connection 
through a suitable communication link 36 via a wireless link 
or a computer network such including an intranet or a global 
computer network link such as an internet link (such as the 
world wide web), etc. 
In certain embodiments, the CCD detector 32 in the 
spectrometer is of a red-shifted, back-thinned, thick epitaxial 
design such that its sensitivity is optimal in the 700-1100 
55 nanometer spectral region. Other types of suitably sensitive 
detectors and spectral ranges may be suitable as well. 
As noted above, a signal processor 32s such as a digital 
signal processor in a general purpose or special purpose 
computer processes the output of the detector 32. The signal 
60 processor or computer or other controller can control the 
laser beam frequency and the power or intensity of the laser 
pulse from the laser source 10. 
In some embodiments, the signal processor 32s, 
computer, or controller can switch the frequency of the laser 
65 to permit subtraction of fluorescence as described previ- 
ously. The signal processor or computer can also direct 
information to a digital display imaged onto the retina. The 
35 32. 
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patient can then read the results of the analysis on this contact the cornea of the eye during use, which many 
display. For certain embodiments, the results can be dis- patients find objectionable (e.g., by providing a suitable 
played on the exterior of the device so that a clinician or monocular eye cup for contacting the orbit around the eye). 
police officer (the latter being particularly directed for nar- The apparatus of the invention can be implemented as a 
cotics or blood alcohol evaluations) can easily read same. 5 spectrometer base unit attached by a fiberoptic cable to an 
Further, the data or results can be date and time coded and ocular probe, or as a single integrated unit including 
digitally stored and Printed as a medical Or Police record. foreoptics, spectrometer, detector, computer and display. 
As shown in FIG. 6, fibers 40, 41 may be used to deliver The apparatus can be configured as a relatively lightweight 
the laser beam and collect the Raman scattered light. In and portable device. In some embodiments, the optics and 
certain embodiments, the confocal aperture is a circular 10 laser source can all be configured to be held in a housing 
aperture 42 placed on the end of a multimode fiber. As with which can be mounted on the user as a headset, or on a 
the pinhole aperture shown in FIG. 5,  the end of the fiber can portable platform device similar to vision screening or 
be placed so that it is confocal with the objective lens’ focal vision correction devices used during vision exams. 
point in the anterior chamber of the eye. Asingle mode fiber noted above, a visual fixation target such as a mirror, 
can be used to direct the laser beam into the anterior 15 LED, or display such as an active liquid crystal matrix 
chamber of the eye. This single mode fiber can help facilitate display or the like can be built into the optical apparatus such 
a diffraction limited spot size at the focal point of the that it is heid in the housing in visual communication with 
objective. the patient or user during operation to facilitate focusing of 
Afiber delivery and collection system like that depicted in the excitation light into the anterior chamber and maintain 
FIG. 6 can be connected to alternative detection systems, 2o stability of the eye (so that it is properly aligned with the eye 
one of which is shown in FIGS. 7a-b. This alternative of the subject). In the embodiment of FIGS. 5-7, a display 
detection system can allow for subtraction of the fluores- screen such as a liquid crystal display is employed. As 
cence spectrum as well as selected sampling of the frequen- shown in FIG. 8, a blinking fixation target in the form of an 
cies most important for calculation of glucose concentration. hourglass 70 can be displayed, focused on the retina, during 
Such an alternative detection system may decrease the size 25 acquisition of the spectra by the apparatus. Other fixation 
and cost of the instrument. The system depicted in FIG. 7 target forms can also be used such as text, letters, numbers, 
uses one or more fixed frequency or tunable lasers to or other recognizable shapes or objects. This can help 
illuminate the aqueous humor of the eye using the optical optimize the Raman signal from the aqueous humor and 
delivery system shown in FIG. 6. reduce light exposure to other structures of the eye. The 
FIG. 7a illustrates that each spectral feature 50a, 50b, 50c 30 fixation target can be active during the time that the laser 
of the Raman scattered light is related to the excitation beam is active and illuminating the subject’s eye. 
wavelength by a fixed offset, usually expressed in wave- As shown in FIG. 9, in some embodiments, a visible 
numbers. Changing the excitation wavelength causes the indication of the results of the test in the form of alphanu- 
Raman spectra to shift in wavelength, as depicted by the 35 meric indicia 71 (or other suitable form, such as a graphical 
different feature or portion of the signal, captured in detector display) can be displayed on the same screen immediately 
range window A, 51 (a relatively narrow band of the signal after the acquisition step (or to a remote or externally visible 
such as about 10 nm) based on Raman spectra 52 for screen for other embodiments). The indicia of FIG. 9 pro- 
excitation frequency L,, as compared to Raman spectra 53 vides a readout for all of the principal Raman-active com- 
for excitation frequency LX2. 4o pounds of the aqueous humor, but the display can be of a 
apparatus that takes advantage of the foregoing is targeted compound of interest (filtered from the overall 
schematically illustrated in FIG. 7b. Like components to spectra) CorresPonding to one Or more, of a desired concen- 
FIGS, 5 and 6 are assigned like numbers, L~~~~ drivers tration level of a selected substance (such as alcohol) as 
and/or tuning electronics 60 are operatively associated with desired. 
a tunable laser or a plurality of fixed wavelength lasers 61, 45 In some embodiments, a motion sensor can be incorpo- 
62, 63. A series of one or more bandpass filter/detector rated into the device so that the test can be aborted upon 
elements 65, 66, 67 operatively associated with amplifiers movement of the eye away from the focal point or SO that a 
and an analog to digital converter 68 is used to sample the clinician is alerted as to the movement. For example, upon 
spectrum of the collected light. The center wavelength and transmission of the laser pulse to the selected region in the 
bandwidth of each filter may be chosen to correspond with eye, a sensor can be concurrently operated and used to detect 
a different Raman spectral peak of aqueous humor important movement of the retina away from the target focal point. 
for quantification of the selected substance (such as alcohol, The excitation laser light source can be any suitable laser 
an illegal narcotic or banned substance, a poison, or beam source which can generate a suitable laser beam signal 
glucose). If this laser is tunable over about a nanometer or at a desired frequency output. A distributed feedback laser 
so, subtraction of the fluorescent components of the acquired 55 can be used to reduce instrument size. Tunable or multiple 
spectrum may be possible as discussed earlier. Using a laser fixed frequency lasers can be combined with bandpass filters 
with a wider tuning range can allow the Raman shifted (Puppels et al., Applied Spectroscopy 47, 1256-67 (1993)) 
spectra to be scanned or slid across a smaller number of that can generate pulses for Raman scattering at wavelengths 
bandpass filteddetectors. Since semiconductor lasers with that provide optimum information for multivariate analysis 
extremely wide tuning ranges are not commercially readily 60 (this can reduce the cost and size of the instrument compared 
available, one may instead use a set of narrowly tunable to the use of holographic filters or gratings). 
lasers each with a different center wavelength as the laser The laser beam can be pulsed from the generator or from 
means in conjunction with a series of bandpass filter/ the optical system to provide the desired length and power 
detectors for this purpose. Other suitable light sources can or energy to the tissue in the eye, ne power ofthe excitation 
also be used. 65 laser beam pulse should be sufficiently low to avoid tissue 
Advantageously, the systems described herein may be toxicity, but sufficiently high to provide a measurable Raman 
configured so that optical components need not and do not signal from the aqueous humor. In general, the laser beam 
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pulse will be at a wavelength of from 400 to 900 nanometers. mined substance of interest (but is above 400 nm). As used 
In some embodiments, the laser wavelength can be a wave- herein, the term “resonant Raman” means an excitation 
length of 780 to 860 nanometers to reduce fluorescence, wavelength that amplifies the (detected) Raman signal at 
increase tissue penetration, and reduce phototoxicity to the least about 100 times over non-resonant or weakly resonant 
eye. In other embodiments, the wavelength can be generated s excitation wavelengths and/or relative to the normal baseline 
at a lower wavelength, such as between 400-700 chemicals present in the eye; this term is intended to include 
nanometers, so as to increase the signal to noise ratio of the strongly pre- or post-resonant wavelengths. 
signal and/or to decrease the power level of the signal in the The above design may be particularly suitable to detect 
eye. substances with a molecule of interest that is resonant or 
The duration of the pulse can be from 1 to 60 seconds in 10 pre-resonant in the 400-1000 nm range. Some molecules, 
length, and typically is from about 5-20 seconds long. notably ethanol, are not resonant over this range, but have a 
The total energy of the laser pulse transmitted to the eye Peak that is relatively strong at high PhYsiological concen- 
will typically be between 7&500 millijoules, with instan- trations in which it is used (such as recreational intake). The 
taneous power preferably not exceeding about 30-50 milli- same instrument design therefore can be used to test for 
watts, The optical components of the apparatus used to carry ethanol since the blood concentration can be relatively high 
out the method are preferably configured so that energy on (0.01-0.4%) (such as to test for drivers that may be 
the retina of the eye (as well as other areas susceptible to impaired). Of course, this rationale applies to other analYtes 
tissue toxicity, such as the lens and cornea) transmitted from Or substances that may be Present in increased blood con- 
the excitation laser beam pulse is not greater than 3000 centrations. N S O ,  if a molecule is not going to be resonant 
mW/cm’, more preferably not greater than 100&2000 2o or strongly pre-resonant, then the excitation wavelength can 
mW/cm’, and even more preferably, below about 500 be chosen to avoid Or reduce fluorescence-~s~allY by 
mW/cm’. employing an excitation wavelength in the range of about 
In certain embodiments, a low energy excitation wave can 600-900 nm. 
be used to generate the Raman signal spectrum. “Low 25 Typically, the excitation wavelength is above 400 nm 
energy”, as used herein, means power which is on the order (between about 4N-600 nm) and corresponds to a Portion 
of about 10400 mJ or less, and typically between about of the absorption spectrum. Absorption is non-negative since 
70-330 mJ. The energy exposure will depend on the power it is defined as the -log (% transmission). The excitation 
and pulse length of the excitation pulse. Longer wavelength wavelength can be chosen to increase Or maximize the signal 
pulses (i.e., above 700 nm) may be used, typically with to noise ratio. This can be done by making the signal bigger, 
energy closer to the higher end of the scale, while lower 30 by inducing resonant Raman by selecting an excitation close 
wavelengths (400-700 nm) may be able to employ lower to the absorption band of the molecule (but above 400 nm) 
energy exposure levels. In one embodiment, a wavelength of Or by reducing the n0iSe-i.e. reducing fluorescence by 
about 633 nm can be used for a pulse of about 5-10 seconds operating at a longer wavelength (e.& 785 nm) for sub- 
corresponding to about a 2 mW power exposure level and stances that cannot be made Raman resonant Or strongly 
between a 10-20 mJ energy exposure to the patient’s eye for 35 pre-resonant in the 400-1000 nm range. The signal enhance- 
each measurement or monitoring signal obtained. In other ment for resonance is sufficiently increased that one should 
embodiments, an optical excitation pulse may have a 785 nm attempt to induce it when possible. However, it is noted that, 
wavelength (or other suitable wavelength), and a pulse in Practice, many molecules may not be resonant Or strongly 
length of about 20 ms and a power rating of about 15 mW. pre-resonant in the 40&1000 nm wavelength range although 
In another embodiment, a 5 set, 16 mW pulse (having a 40 certain drugs or other analytes Of interest may be resonant or 
energy exposure level of about 75 mJ) can be used to obtain strongly Pre-resonant in the 400-600 nm range. In Particular 
the in vivo reading of a substance such as a cancer treatment embodiments, a wavelength of under about 450 nm, such as 
agent in the selected region of the eye (typically the AH). In about 405-410 nm, may be employed. 
The excitation range is chosen to be above 400 nm particular embodiments, an excitation light having a wave- 
length of about 406.7 nm can be employed. The 400 nm because wavelengths below 400 nm may induce the forma- 
excitation wavelength level or range may be particular tion of cataracts. Silicon CCD detectors are typically used in 
suitable where a resonant Raman signal may be generated by Raman spectrometers. The long wavelength cut-off for these 
a selected substance or molecule. detectors is slightly over 1000 nm. Therefore, to allow for 
For multiple measurements, the devices may be able to be Raman shifted light, the device can be configured to operate 
configured to focus on a different eye, alternating the eye to with an excitation wavelength range from about 4 0  
which the light is transmitted, to reduce the amount of nm 
exposure to any one eye. The device can be configured to provide an exposure time 
FIG. 30 illustrates yet another embodiment of a device *he *” *he light) of about seconds Or less 
mW, and typicah’ 
45 
On the 
suitable for obtaining a Raman spectra of the eye of a 55 with an associated power Of about 
subject. This device is compact, portable, and inexpensive, about mW. 
typically requiring only a diode laser, a filter, lens, and As shown in FIG. 30, the device can be configured with 
detector. The device can be directed to operate at a fixed a sine wave generator 10s  operably associated with the 
excitation wavelength. As shown, the device includes a diode laser 1OL and the detector 32 to modulate the signal 
relatively inexpensive diode laser lOL, an optically-formed 60 and improve SNR. Amixer 10M can be used to integrate the 
notch filter 21, a detector 32, and a beam splitter 17. In sine wave generator 1 0 s  and the detector 32 with the low 
certain embodiments, the diode laser 1OL has a fixed opera- pass filter 1OF as is well known to those of skill in the art. 
tional wavelength. Typically the device is configured to In certain embodiments, the device can be configured so 
detect a predetermined substance and, as such, the excitation that, in operation, the sine wave generator 10s  modulates the 
wavelength of the laser is pre-selected to correspond to a 65 laser light. Generally stated, the detected light is Raman 
wavelength that substantially corresponds to or approaches scattered off the sample and is modulated in a similar 
the resonant Raman (“RR’) wavelength for the predeter- fashion. The detector measures this intensity and converts it 
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into an electrical current. The detector also picks up noise 
from the ambient light and other sources. The mixer 10M 
multiplies this detected signal by a reference sine wave, 
producing a signal. The low pass filter rejects the high 
frequency terms and passes the low frequency term of the 
Raman scattered light. Thus above-described operation may 
be described as coherent signal detection and is a detection 
technique commonly exploited by lock-in amplifiers. As is 
known to those of skill in the art, other designs may also be 
used such as without modulation of the laser beam and/or 
post-processing module. 
In certain embodiments, the device can be configured 
with improved signal to noise ratio of the overall instrument 
by post-processing the detector 32 signal by using coherent 
detection, similar to methods employed by a lock-in ampli- 
fier as is well known to those of skill in the art. 
FIGS. 26 and 29 illustrate a RR spectrum generated at 
406.7 nm excitation wavelength for two different substances 
of interest, the peaks having increased intensity over spec- 
trums generated at non-resonant or weakly resonant wave- 
lengths. FIG. 26 illustrates the RR spectrum of a chemo- 
therapeutic agent and FIG. 29 illustrates the RR spectrum of 
an anti-fungal agent. However, even for non-resonance 
wavelengths that approach the peak absorption wavelength 
of the compound, the Raman signal intensity may increase 
sufficiently to serve as an acceptable operable excitation 
wavelength. The particular excitation wavelength will 
depend on the drug or analyte of interest and can be selected 
so that, in operation, it can amplify the detected intensity of 
the Raman spectrum signal substantially, such as by about 
100 times to 1,000 or greater (even up to about 100,000 
times in certain circumstances) over that of signals gener- 
ated with excitation signals that depart greater than 200 nm, 
away from the peak wavelength in the absorption spectrum. 
As such, in certain embodiments, the excitation wavelength 
may be chosen so that it is about 100 nm or less above the 
peak absorption wavelength in the absorption spectrum. 
The device can be configured to detect a single peak of 
interest in the RR spectrum (at a predetermined wavelength 
shift of interest), such as the peak at 1576icm or 117licm in 
FIG. 26 or the peak at 1152icm or 1554icm in FIG. 29. Of 
course, as noted above in other embodiments, the device can 
be configured to detect multiple peaks or at multiple wave- 
lengths (adding notch filters or a tunable laser, and the like, 
as is well known to those of skill in the art). 
In certain embodiments, the chemical or analyte concen- 
tration in the blood can be measured within a 90-99% 
accuracy level as determined by extracting the aqueous 
humor, putting it in a test tube and measuring the Raman 
spectrum. The band of interest is typically in the 200-3200 
cm-I band. 
Any suitable detector 32 can be used to detect a Raman 
spectrum from illuminated aqueous humor. In certain 
embodiments, a CCD detector or CCD camera can be used 
to detect reflective light as they may exhibit increased 
sensitivity over other types of detectors. The CCD detector 
preferably is configured to have high quantum efficiency in 
the near infrared range. The high quantum efficiency may be 
achieved by any suitable means, such as employing a back 
thinned detector, but one sufficiently thick to reduce etalon 
effect. 
The devices of the invention can be operatively associated 
with a patient’s medical equipment such as an insulin pump 
(for D-glucose) or to a dialysis machine (for urea) by 
wireless or wired electrical or fiber optic lines, radio fre- 
quency transmitters and receivers or the like to provide 
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information on the appropriate analyte that can then be used 
to control that equipment. For example, the reading can be 
used to automatically activate or increase or decrease the 
output of the equipment such as the insulin pump in response 
5 to blood glucose levels, or to regulate the dialysis machine. 
In telemedicine applications, the instrument of the inven- 
tion can be conveniently operatively associated with a 
remote read-out terminal through a communication link such 
as a telephone, cable, computer, modem, intranet, internet 
connection or other communication line with any suitable 
relay or interconnection means (such as an electrical or fiber 
optic lines, radio frequency transmitters and receivers, etc.) 
to provide information on the blood or intracranial (blood- 
brain fluid) analyte to a remote physician or medical pro- 
15 vider (e.g., through a telephone, cable, or wireless connec- 
tion to a direct security (for in-home parole) or medical 
monitoring agency or to a selected destination on the 
intranet, internet, or world wide web). 
FIG. 11 illustrates method steps for obtaining spectro- 
2o graphic readings of the selected region of the eye of a subject 
according to certain embodiments of the present invention. 
As shown, an excitation or illumination light pulse is trans- 
mitted to the selected region of the eye of the subject (Block 
100). In certain embodiments, this can be carried out by 
25 positioning a mask-like device over the eyes of the subject 
(similar to that used in eye exams) so that (a) the housing of 
the device aligns over the eye socket(s) to seal the eye(s) 
from ambient lighting, (b) the excitation pulse light is 
efficiently directed into the eye (without scattering into the 
30 environment), (c) and the light reflected from the eye (such 
as the AH) can be captured, but no physical contact with the 
cornea of the eye itself is required. For example, a monocu- 
lar eye cup (or binocular eye cups) can be used to contact the 
orbit around the eye and yet space the optical components 
35 from contacting the cornea. The scattered light from the 
illumination light pulse is then detected (Block 120). 
During the transmission and detection steps, the eye can 
be focused to a desired location or target spot (Block 105) 
to help direct the excitation light out of and into the eye in 
40 a repeatable and reliable manner (to define a consistent 
transmission path so that the reflected light is attributed to 
proper and reliable illumination of the VH, AH, or conjunc- 
tiva vessel(s)). In so doing, a manual or autofocusing 
technique can be used. For manual focusing, various meth- 
45 ods can be used to allow the user to adjust the focus. For 
example, a pinwheel can be turned clockwise or counter- 
clockwise to focus on an object or text or other visual 
fixation target to be displayed in the device (typically the 
object or text is displayed in a miniaturized display (such as 
50 an active matrix display) positioned about the opening 
through which the light is transmitted proximate the light 
transmission path). For example, LED’s or active matrix 
displays can be used to generate text or a blinking or 
continuous light, which attracts the visual attention of the 
5s subject and which the subject watches or reads during the 
transmission and detecting steps. 
Similarly, for autofocusing, the subject can look to the 
visual fixation target mounted in the device in visual com- 
munication with the eye. The presentation of the object can 
60 be automatically stepped through a visual protocol which 
can magnify or adjust the visual presentation until the 
subject can read or recognize the object. When this happens, 
the reading or recognition indicates that the focus is 
sufficient, and the reading can be taken (i.e., the transmission 
65 and detection of light). Autofocusing systems with corrected 
optic systems are well known to those of skill in the art. For 
example, optic systems similar to those used to assess vision 
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and determine a suitable lens correction for a subject during 
vision examinations can be incorporated into the devices 
according to embodiments of the present invention. 
Although a contact lens may remain in Place during the 
reading, it is Preferred that glasses Or other objects which s 
may physically interfere with the mounting of the device 
over the eyes, be removed during the test. 
The power or beam strength of the light pulse can be 
monitored so that fluctuation in the power or strength of the 
1703-1707 (1983); Kisner et al., Simultaneous Determina- 
tion of Triglycerides, Phospholipids, and Cholesteryl Esters 
by Infrared Spectrometry, Anal. Chem., 54; 1479-1485 
(1982); Lam, R. B. On the Relatiomhip of Least Squares to 
Cross-correlation Quantitative Spectral Analysis, Appl. 
Spec,, 37; 567-569 (1983); Maris et al,, Nonlinear Multi- 
component Analysis by Infrared Spectrophotornetry, Anal. 
Chem., 55; 1694-1703 (1983); McClure, G. L. et al. Appli- 
cation of Computerized Quantitative Infrared Spectroscopy 
light beam which is transmitted to the user can be adjusted 10 to the Determination of the PrincipalLipids Found in Blood 
SO that it the current and/or heat is regulated to be substan- Serum, Computerized Quantitative Infrared Analysis, 
tially constant (constant current or heat) or numerically ASTM STP 934, G. L; McClure, Ed. American Society for 
corrected for, typically in the signal processor 35s (Block Testing and Materials, Philadelphia, 13; 1-154 (1987); Otto, 
110).ARaman spectrum of the targeted region of the eye can M. et al. Spectrophotometric Multicomponent Analysis 
spectroscopic signal (Block 130). Typically, well-known 63-69 (1985); Antoon et al. Factor Analysis Applied to 
generate the Raman spectrum from the scattered light data 351-357(1979); Are et al., On the Effect of Calibration and 
received at the detector. See e.g., Standard Practices for theAccuracy ofNIR Spectroscopy with High Levels ofNoise 
Infrared, Multivariate, Quantitative Analysis, ASTM E 20 in the Reference Value, Appl. Spec. 45; 109-115 (1991); 
Calibration and Analysis, Anal. Chem. 59, 1007A-10017A Resolution Techniques. I .  The Method and its Application to 
(1987); Draper et al., Applied Regression Analysis (2d ed., Self-Association ofAceticAcid, J. Phys. Chem. 77; 256-262 
John Wiley and Sons, 1981); Maliowski et al., Factor (1973); Culler et al. Factor Analysis Applied to a Silane 
Analysis in Chemistry (2d ed., John Wiley and Sons, 1991); 2s Coupling Agent on E-Glass Fiber System”, Appl. Spec., 38; 
Mark, H., Principles and Practice of Spectroscopic Cali- 495-500 (1984); Dale et al., Principal Component Analysis 
bration (John Wiley and Sons, 1991); Martens et al., M d -  of diffuse Near-Infrared Reflectance Data From Paper 
tivariate Calibration (John Wiley and Sons, 1989); and Currency, Appl. Spec., 43; 1399-1405 (1989); Gillette et al., 
McClure, G., Ed., Computerized Quantitative Infrared Noise Reduction via Factor Analysis in FT-Zr Spectra, Appl. 
Analysis, ASTM STP 934, ASTM (Philadelphia, 1987). The 30 Spec., 36; 535-539 (1982); Kargacin et al. Ion Intensity and 
contents of these references are hereby incorporated by Image Resolution in Secondary Ion Mass Spectrometry, 
reference as if recited in full herein. Anal. Chem., 58; 2300-2306 (1986); Lindberg et al., Partial 
Thus, any number of suitable computational analysis may Least Squares Method for Spectrofluorimetric Analysis of 
be used including linear (e.g., algebraic or least squares/ Mixtures of Humic Acid and Lignimulfonate, Anal. Chem., 
partial least squares) or nonlinear (e.g., artificial neural 35 55; 643-648 (1983); Lukco et al., The Use of GC-AES 
networks) multivariate analysis techniques, such as, mul- Multielement Simulated Distillation for Petroleum Product 
tiple linear regression (MLR), classical least-squares (CLS, Fingerprinting, J. Chrom. Sci. 1993, March; Malinowski et 
K-matrix), inverse-least-squares (ILS, P-matrix), principal al. Factor Analysis in Chemistry, 2nd edition, John Wiley 
component regression (PCR, PCA, factor analysis), and and Sons, New York, 1991; Malinowski, E. R., Theory of the 
partial least-squares in latent variables (PbS). See Schulze et 40 Distribution of Error Eigenvalues Resulting from Principal 
al., Artificial neural network and classical least squares Component Analysis with Applicatiom to Spectroscopic 
methods for neurotrammitter mixture analysis, Jnl. Neuro- Data, J. Chemo., 1; 3 3 4 0  (1987); Malinowski, E. R., 
science Methods 56(2); 155-167 (February 1995); and Statistical F-Tests for Abstract Factor Analysis and Target 
Wang et al.,Analysis of metabolites in aqueous solutions by Testing, J. Chemo., 1; 49-60 (1987); Malinowski, E. R. 
using laser Raman spectroscopy, Applied Optics, 32(6); 45 Theory of Error in Factor Analysis, Anal. Chem., 49; 
925-9 (February 1993). See also Brown, C. W., Classical 606-612 (1977); Malinowski, E. R., Determination of the 
and Inverse Leastsquares Methods in Quantitative Spectral Number of Factors and the Experimental Error in a Data 
Analysis, Spectrosc., 1; 23-37 (1986); Brown, et al., “Matrix Matrix, Anal. Chem., 49; 612-617 (1977); Naes et al., 
Representations and Criteria for Selecting Analytical Wave- Selection of Samples for Calibration in Near-Infrared Spec- 
lengths for Multicomponent Spectroscopic Analysis”, Anal. SO troscopy. Part I: General Principles Illustrated by Example, 
Chem. 54; 1472-1479 (1982); Carey et al., Multicomponent Appl. Spec. 43; 328-335 (1989); Rao et al., FactorAnalysis 
Analysis using an Array of Piezoelectric Crystal Sensors, and Leastsquares Curve-Fitting of Infrared Spectra. An 
Anal. Chem., 59; 1529-1534 (1987); Haaland, D. M. Clas- Application to the Study of Phase Transitions in Organic 
sical versus Inverse Leastsquares Methods in Quantitative Molecules, Appl. Spec., 38; 795-803 (1984); Schostack et 
Spectral Analyses, Spectrosc. 2; 56-57 (1987); Haaland et ss al., Preferred Set Selection by Iterative Key Set Factor 
al. Application ofNew Least-squares Methods for the Quan- Analysis, Chemo. and Intel. Lab. Sys., 6; 21-29 (1989); 
titative Infrared Analysis of Multicomponent Samples, Appl. Vaughan et al., Determination of Ni by ICP-MS: Correction 
Spec., 36; 665-673 (1982); Haaland et al., Improved Sen- of Oxide and Hydroxide Interferences Using Principal Com- 
sitivity of Infrared Spectroscopy by the Application of Least ponentsdnalysis, Appl. Spec., 44; 1685-1689 (1990); Carey 
Squares Methods,Appl. Spec. 34; 539-548 (1980); Haaland 60 et al., Multicomponent Analysis using an Array of Piezo- 
et al. Multivariate Least-Squares Methods Applied to the electric Crystal Semors, Anal. Chem., 59; 1529-1534 
Quantitative Spectral Analysis of Multicomponent Samples, (1987); Donahue et al., Analysis of Deoxvribonucleotides 
Appl. Spec., 39; 73-84 (1985); Kargacin et al. Ion Intensity with Principal Component and Partial Least-Squares 
and Image Resolution in Secondary Ion Mass Spectrometry, Regression of W Spectra after Fourier Processing, Appl. 
Anal. Chem. 58; 230Ck2306 (1986); Kisner et al. Multiple 65 Spec., 44; 407413  (1990); Geladi et al., Partial Least- 
Analytical Frequencies and Standards for the Leastsquares Squares Regression. A Tutorial, Anal. Chim. Acra, 185; 
Spectrometric Analysis of Serum Lipids, Anal. Chem., 55; 1-17 (1986); Haaland et al., Partial Leastsquares Methods 
then be generated based on the detected and corrected light 1s Applied to Trace Metal Determinations, Anal. Chem., 57; 
statistical correlation or normalization techniques are used to Fourier Transform Infrared Spectra, Appl. Spec., 33; 
1655-97; Beebe et al., A n  Introduction to Multivariate Bulmer et al. Factor Analysis as a Complement to Band 
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for Spectral Analysis 1. Relation to Other Quantitative 
Calibration Methods and the Extraction of Qualitative 
Information, Anal. Chem., 60; 1193-1202 (1988); Haaland 
et al., Partial Leastsquares Methods for Spectral Analysis 
2. Application to Simulated and Glass Spectral Data, Anal. 
Chem., 60; 1202-1208 (1988); Hanna et al., A Comparison 
of Methods Used for the Reconstruction of GCIFT-17R 
Chromatograms, J. Chrom. Sci., 17; 423-427 (1979); Kelly 
et al., Prediction of Gasoline Octane Numbers from Near- 
infrared Spectral Features in the range 660-121 5 nm, Anal. 
Chem., 61; 313-320 (1989); Lindberg et al., Partial Least- 
Squares Method for Spectrofluorimetric Analysis of Mix- 
tures of Humic Acid and Ligninsulfonate, Anal. Chem., 55; 
643-648 (1983); and Otto et al., Spectrophotometric Mul- 
t icomponent  Ana lys i s  A p p l i e d  to Trace Meta l  
Determinations, Anal. Chem., 57; 63-69 (1985). The con- 
tents of these references are hereby incorporated by refer- 
ence as if recited in full herein. 
FIG. 1OC illustrates that the device 5 may include a closed 
loop feedback system 5f for monitoring and regulating the 
strength or intensity of the light excitation beam output to 
the eye of the subject. The feedback system 5fmay employ 
a beam splitter positioned to bleed off a portion of the beam 
at a location which is proximate to the aperture (the beam 
outlet port) and substantially continuously detect the beam 
power, intensity, or energy associated therewith to monitor 
the power of the excitation beam as it is transmitted out of 
the device. Other embodiments can include dynamically 
monitoring the current or power load of the laser 10 to adjust 
for temperature or other operational drift or power fluctua- 
tion during operation. The signal processor 35s can then 
adjust the input to the laser as needed and/or store the 
excitation beam data so that the Raman spectrum can be 
adjusted to reflect the actual beam energy or power trans- 
mitted to the user. 
FIG. 10D illustrates one operational embodiment of a 
device with power regulation according to the present inven- 
tion. As shown, the laser 10 is operably associated with a 
power supply lop.  The laser 10 directs the light through a 
fiber optic cable 40 which includes or is coupled to a fiber 
optic splitter 40s which directs or bleeds a small portion of 
the light away from the primary light transmission path (and 
into the eye of the patient). Asubstantial portion of the light 
remains in the primary light transmission path and is 
directed into the Raman probe head 15 probe which can, in 
operation, be positioned adjacent the eye 12 of the patient. 
The Raman spectrometer 32 can be positioned in commu- 
nication with the Raman probe so as to be able to detect the 
light upon its return (in the return path). 
As shown, the splitter 40s may split about 1% of the 
excitation light away from the primary beam to a detection 
path 115 and into a photodetector 116 (or other suitable 
sensor). The photodetector 116 is in electrical communica- 
tion with an AID (analog to digital) converter 118, which 
converts the corresponding electrical signal so that it can be 
digitally input into the processor 35. Thus, the voltage or 
current from the photodetector 116 is measured and digitized 
(preferably in a substantially continuous or continuous man- 
ner during operation of the device) and the information 
transmitted to the processor 35 (typically a computer). The 
computer or processor 35 can then measure the laser power 
and computationally determine a new adjusted current (or 
voltage) to adjust the laser 10 output to the desired or target 
output value such that it is able to be held to within about 
95% of the target output strength. In certain embodiments, 
the output signal strength can be held substantially constant 
such as within at least about 98-99%. The computer output 
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can be converted back into analog form via a DIA converter 
119 which is used to regulate the voltage power supply l op  
which, in turn, regulates the input to the laser 10. 
The optical system 15xi may also be configured to trans- 
5 mit the excitation beam such that it presents a wider cone to 
focus to the retina in a manner which is able to cover a larger 
area of the selected region in the eye to thereby operate with 
a lower energyiarea ratio (such as, for at least some AH 
applications, configuring the optical system such that the 
10 numerical apertures of the input optic system 15xi is sub- 
stantially matched to the output optic system 15x0 (or 
spectrometer). In certain embodiments, a numerical aperture 
of about 0.2-0.5 can be used. The graph in FIG. 20C shows 
a sample power density and exposed retinal area for a 
15 numerical aperture of 0.25 and a lox objective (Point A) and 
a larger numerical aperture of about a 0.4 (23.6 degrees for 
a 20x objective) at Point B. 
FIGS. 20A-20C illustrate optical power density calcula- 
tions performed using a canonical model of the adult eye of 
20 a human (FIG. 20A). Typically, optical toxicity power 
limitations for the eye are established by regulatory agen- 
cies. 
FIG. 20A shows a diagram of the adult eye exposed to 
light through an eyepiece with a corresponding objective 
25 and numerical aperture. Marginal rays from this eyepiece are 
shown focusing through the cornea and into the aqueous 
humor within the anterior chamber. The confocal optical 
configuration of the instrument allows it to sample Raman 
scattered light in the region near the focal spot (and sub- 
30 stantially isolated to that region). Thus, in certain 
embodiments, the optic design can be such that scattering 
from the cornea or the intraocular lens can be reduced and 
can be confocally blocked from the instrument's fiber-optic 
entrance aperture within the optical probehead (FIG. 10d, 15 
FIG. 20A also shows the nodepoint (N) originally derived 
by Gullstrand. Gullstrand used special instrumentation to 
observe Purkinje reflections from both sides of the cornea 
and lens to develop a simple eye model which lumped the 
40 power of the cornea and the intraocular lens into a single 
equivalent lens with node point (N). Based on the knowl- 
edge of the position of node point (N) relative to the retina, 
one can calculate sizes of objects on the retinal surface. This 
information can be used to compute the surface area of the 
45 retina exposed by the numerical aperture (NA) (such as 
NA=0.25 or NA=0.4 according to certain embodiments of 
the design of the device and the associated eyepiece). 
In this model, rays passing through (N) can be treated as 
if they are unrefracted as they travel through the eye and 
50 onto the retina. One can construct rays that pass through (N) 
but are also collinear with the eyepieces marginal rays as 
shown. A pair of collinear rays entering the lens equivalent 
model should focus on the retina. Going through this exer- 
cise with both pairs of marginal rays of the eyepiece shows 
55 that one can treat the incident beam as a point source which 
emanates from (N) at an angle Bi, the same angle as the 
marginal rays make with the optical axis. 
As shown in FIG. 20B, simple calculus can be employed 
to derive an expression for the surface area of a sphere over 
6o a solid angle delineated by Bc, the angle of a ray from normal 
that extends to the margins of the surface area exposed on 
the sphere. The expression for surface area is given by 
equation 1. 
35 probe). 
Equation 1 65 A=2nRZ(1-cos e=) 
B i  is given (calculated as sin-' of NA of the eyepiece) and 
not Bc, an expression can be derived which relates these as 
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a function of the radius of the globe and the relative position 
of N given by xo. As shown by equation 2 in FIG. 20B, 
trigonometry can be used to derive this relationship. For any 
Bi, equation 2 can be solved numerically for Bc, using the 
Newton-Rapson method. 
R sin 8,=(R cos8,+xo)tan 8, Equation 2 
FIG. 20C is a graph which plots exposed retinal surface 
area (right vertical axis) and power density assuming a 30 
mW illumination (on the left vertical axis) on the retina as 
a function of various eyepiece designs defined by the angle 
of incidence “Bi”. The line indicated at the angle of inci- 
dence just below 15 degrees (Point A) corresponds to the 
numerical aperture 0.25 used for obtaining certain of the 
experimental data shown or described herein. The angle of 
incidence associated with a numerical aperture of 0.4 is at 
about 23.6 degrees (larger exposed retina area and lower 
power density), shown at Point B, used to obtain the data 
illustrated in FIGS. 21A-C. This angle can also be expressed 
in terms of NAor “f”-number (the focal length divided of the 
fully illuminated diameter of the limiting aperture). The 
numerical aperture of the entire system places an upper 
bound on the effective numerical aperture. For example, the 
numerical aperture of the embodiment of the device 5 of the 
spectrometer used to determine certain of the described 
results is fi1.8 (NA=0.267). However, the fiber optic cable 
between the spectrometer and the probe head, limits the 
numerical aperture to fi2.0 (NA=0.24). Thus using an objec- 
tive at a higher f number than the fiber is counterproductive 
since Raman scattered light at the outer angles is not 
captured by the fiber. Using the instrument with the same 
incident power but with an objective with an f number 
smaller than f/2 will generally result in higher power den- 
sities on the retina with no increase in Raman signal gain. 
This is because maximum collection efficiency is achieved 
at a particular by matching the f number of the eyepiece to 
that of the system. The present invention can provide 
designs which can be considered close to optimal, by 
configuring the system with an f number which is approxi- 
mately equal to the eyepiece numerical aperture. Using 30 
mW of illumination, one embodiment can provide a lens 
configuration which exposes about 0.58 cm2 of the retina to 
a power density of about 51.5 mW/cm2. 
FIG. 18 illustrates that the illumination target in the eye 
can be the vitreous humor, a substantially clear gel-like 
region positioned beyond the aqueous humor. The devices 
described herein can be configured to operate similarly to 
that for the AH target, i.e., by transmitting the excitation 
beam to a deeper depth into the eye and into the VH (through 
the lens and/or the portion of the eye accessible when the eye 
is open), illuminating same and then detecting the transmit- 
ted light returned therefrom. The energy levels are prefer- 
ably as noted above for the AH. As the Raman signal from 
VH may exhibit increased fluorescence, signal correction 
(subtraction, differentiation, etc.) may be used to obtain/ 
detect the desired signal data. 
FIG. 19 illustrates that the illumination target in the eye 
can be one or more blood vessels located on the conjunctiva 
at the outer surface of the eye. Using the conjunctiva 
vessel(s) can allow a direct blood level measurement to be 
obtained as this embodiment can focus to the blood flowing 
in the vessel (i.e., the blood itself to directly determine the 
targeted blood level measurement). In operation, the exci- 
tation beam is focused to at least one blood vessel on the 
externally accessible surface of the eye to illuminate the 
blood flowing in the blood vessel (because the blood vessel 
is located on the outer surface of the eye, there is no need to 
30 
illuminate through skin). The targeted blood vessel can be 
any of the blood vessels located on or adjacent the conjunc- 
tiva of the eye (typically these are visually apparent), such 
as the long ciliary arteries or veins. One suitable target 
s location may be one of the blood vessels located outside the 
iris away form the pupil. The detected Raman spectrum 
signal can be analyzed and a direct blood level measurement 
of the analyte of interest obtained. In certain embodiments, 
at least two readings can be taken to obtain data samples at 
i o  different points of time to watch the spectra change. For 
example, one can attempt to include data associated with the 
vessel at a point in time when the blood cells are absent in 
the illuminated region in the vessel. Further, the Raman 
signal can be processed (discarded or filtered) to remove the 
is data corresponding to red blood cells to enhance the desired 
signal of the analyte of interest (such as glucose). In some 
embodiments, the beam can be altered to disregard the 
Raman signal of the blood portion and to pursue the Raman 
signal of plasma (such as by shuttering the beam to discard 
20 the blood portion or to delay upon detection of signal 
associated with blood). 
In certain embodiments, the fluorescence spectrum for the 
aqueous humor can be subtracted from the Raman spectrum 
by stimulating the aqueous humor with a second excitation 
2s laser light pulse at a wavelength slightly different from that 
of the first pulse (e.g., up to two nanometers from the first 
pulse), and then subtracting one spectrum from the other in 
a processor in accordance with conventional techniques. 
Such techniques are known. See, e.g., Funfschilling and 
30 Williams, Applied Spectroscopy 30, 443 (1976); Baraga et 
al., Applied Spectroscopy 46, 187 (1992); Wicksted et al., 
Applied Spectroscopy 49,987 (1995)). In the alternative, the 
fluorescence spectrum can be subtracted out through the use 
of software or other processing techniques. Thus, the term 
3s “subtraction” as used herein is intended to include tech- 
niques such as filtering as well as taking the derivatives of 
the signal. While not essential, other potentially interfering 
spectra or signals such as Raman scattering from the lens, 
iris, or cornea can also be filtered or subtracted through a 
40 hardware and/or software processor. Water is typically not 
an issue for Raman spectroscopy, but a water spectrum can 
be subtracted if desired. 
For the difference spectrum adjustment embodiments, the 
blood level of the selected substance (or the cerebral spinal 
4s fluid level) for the subject can be determined from the 
difference spectrum by correlating the difference spectrum 
to predetermined spectrums or data representing the con- 
centration of a particular substance. 
The computational analysis can use the differential spec- 
SO trum or the non-differential spectrum depending on the 
desired application (typically associated with the degree of 
fluorescence of the selected region of the eye to determine 
the Raman spectrum and identify the presence of any 
selected spectroscopic profile or “signatures” having peaks 
ss in a spatial region of the spectrum, which, in turn, allows for 
the identification of the presence or concentration of a 
selected substance in the selected region of the eye. The 
correlation can be based on an empirically based model, 
formula, or matrix of test data garnered from an actual 
60 subject or from in vitro samples. The data can be correlated 
and the end results computed in a hardware and/or software 
processor. The model can be obtained through linear (e.g., 
partial least squares) or nonlinear (e.g., artificial neural 
networks) multivariate analysis. 
In some embodiments, it may be important that a refer- 
ence set or reference standards of known substances and 
concentrations be predetermined and stored for computa- 
65 
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tional reference. For example, a training set of Raman levels for the analyte(s) of interest (for the blood level 
spectra can be used. The training set can include samples measurements). Similarly, for the cerebral spinal or intrac- 
from (or representative of) the selected region of the eye ranial fluid, the aqueous humor sample may be a natural 
such as the aqueous humor with a broad range of concen- sample (human or animal), or may be a man-made or 
trations of the Raman scattering metabolites. In the training s surrogate aqueous humor sample created to mimic natural 
set, the principal Raman-scattering metabolites (or “Raman samples, where the level is calculated from a priori knowl- 
active compounds”) should be provided such that they (for edge of the relationship between cerebral spinal or intrac- 
at least the AH this may include glucose, lactate, urea, ranial levels and aqueous humor levels for the analyte(s) of 
ascorbate, and any exogeneous compounds or drugs present) interest. 
preferably do not vary co-linearly with one another among i o  For example, when the analyte of interest is glucose, the 
the samples in the training set. For direct blood measure- training set of samples for the empirical model can comprise 
ments (i.e., the conjunctiva vessel measurements), the at least 20, 25 or 30 aqueous humor spectra samples. The 
Raman active compounds will be those typically present in samples can include varying levels of constituents which 
the blood. The model can be produced with spectra samples correspond to measured blood glucose levels, where the 
obtained from one or more prior subjects, with spectra is principal Raman active compounds in the aqueous humor 
samples obtained from the subject from whom the current samples (glucose, ascorbate, lactate, urea, and preferably 
blood level of the analyte of interest is being determined (in any exogenous compounds such as drugs) vary substantially 
which case that subject would be required to provide a blood non-colinearly among the samples. The physiological levels 
sample for determination of the blood concentration of the of the blood and/or corresponding aqueous humor glucose 
analyte of interest), or from test vials or artificial AH’S with 20 concentration in the test samples can range from 0 or 50 
known concentrations of selected metabolites and/or the mg/dL to 800 or 1,000 mg/dL, typically including at least a 
substance of interest. Thus, for an AH-based measurement, 100, 200, 300 or 400 mg/dL difference in concentration 
a training set can be used, with vials having a plurality of between the sample with the lowest concentration and the 
constituents, those normally present in the eye (including sample with the highest concentration. 
lactate, urea, and ascorbate) and in the substance of interest. zs Turning now to FIG. 12, one embodiment of the invention 
In some embodiments, to provide an atypical training illustrated therein is particularly suited for the non-invasive 
sample, an artificial cover (such as a contact lens) may be detection, identification and/or measurement of poison in the 
intentionally positioned over the aqueous humor being used blood. A plurality of reference standard spectroscopic spec- 
to generate a sample in a training set. This cover or lens can trum signals are generated (Block 150). The reference 
operate to cause the actual AH to have abnormal levels of 30 signals can be converted into data defining peaks and 
lactic acid (a lactic acid build up) as it is inhibited from frequencies and features of interest and the standards can 
normal operation. correspond to in vitro samples of a plurality of different 
Typically, the training set uses at least 10, and more selected substances, and in some embodiments, each pre- 
preferably 20, 25, 30 or more Raman spectra samples (and sented at different concentration levels (Block 155). The 
samples of the corresponding blood levels of each of the 3s data associated with the reference standards can be pro- 
selected analytes of interest) with substantial intersample grammed into a computer or signal processor and made 
variability in the levels of the major Raman scattering available for subsequent use. As noted above, the reference 
metabolites (e.g., glucose, ascorbate, lactate, urea, and any standards can correspond to a plurality of different Raman 
drugs, analytes, or exogenous compounds present). The spectrum data corresponding to a plurality of different drugs, 
concentration of the analyte of interest (in either the blood 40 or typical or common poisonous substances. For example, 
or aqueous humor) preferably varies by at least a factor of Raman signatures of the most prevalent chemicals associ- 
2, 5, 10 or 20 or more from the sample with the lowest ated with pediatric poison control calls or emergency room 
concentration to the sample with the highest concentration. visits can be analyzed in various concentrations to define an 
This may include providing concentrations of constituents associated Raman signature. These can include common 
less than and greatly above their normal levels such as 0.5 4s over-the-counter household drugs or medicinal supplies 
times to 15 times the normal levels (for the AH this can such as the drugs identified by brand names acetaminophen, 
include urea, ascorbate, lactate, and, can also include glu- ibuprofen, isopropyl alcohol, methanol, ethylene glycol and 
cose or other substances of interest, in saline). The mixtures the like, or prescription drugs such as blood pressure medi- 
can be prepared such that they provide a statistically uniform cines (such as HYTRIN), steroids, antibiotics, birth control 
distribution with no biasico-linearity (i.e., 100 different SO pills, and the like, as well as household cleaning chemicals, 
mixtures of four random substances in the test tube). It is pesticides, herbicides, and petroleum products. 
anticipated that the calibration curve can be biased to cluster An in situ Raman spectroscopic reading can be obtained 
a training set biased within the normal or low range (i.e., to of the subject (Block 160). The subject may have been 
be skewed, depending on the application). exposed to an unknown poison or substance. In some 
The concentration ratios or correlations may require ss embodiments, the term “unknown poison or substance” can 
development of the model using subjects with multiple also include an unknown quantity of a known substance. For 
different diseases (e.g., renal failure, diabetes, seizures, example, a guardian acknowledges that a TYLENOL bottle 
mitochondrial myopathics, sickle cell disease, heart failure, was found empty next to a young child, but it is unknown 
blood clots, etc.) and/or other parameters such as gender, how many pills may have been in the bottle. The present 
age, weight, national origin, etc. For human applications, the 60 invention may be able to determine whether a toxic amount 
model may even be determined with spectra samples was consumed. 
obtained from animals, particularly primates. The sample of In any event, the presence (or absence) of at least one 
the selected region in the eye may be a natural sample selected substance in the subject can be identified (Block 
(human or animal), or may be a man-made or surrogate 170). The amount of the identified substance in the selected 
aqueous humor sample created to mimic natural samples, 65 region of the eye of the subject may also be determined. 
where the blood level is calculated from a priori knowledge Based on the amount in the eye, an amount (a) in the blood 
of the relationship between blood levels and aqueous humor and/or (b) in the cerebral spinal fluid or intracranial fluid can 
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be established (anticipating that the amount in the AH can be In one embodiment, the altering step is carried out by 
correlated to either the amount in the blood or the amount in introducing an osmotic agent or chemical (such as a drug 
the cerebral spinal or intracranial fluid), thus allowing the identified by a trade name of MANNITOL) to the subject to 
presence and concentration to be indirectly established or temporarily open the blood brain barrier to allow larger 
estimated based on the detected Presence and/or concentra- s molecules to pass therethrough. In another embodiment, the 
tion in the region Of the (such as the AH) altering step can be carried out by increasing the intracranial 
180). Physiological differences among different Population pressure of the subject (such as by positioning the subject in 
segments may require determination of different correlation a pressurized chamber), 
factors for each population segment (segmented by selected h o t h e r  embodiment is shown in FIG, 14, This embodi- 
parameters of interest such as by age, gender, national i o  ment is directed to a method of non-invasively monitoring origin, etc.) the operationifunction of the blood brain barrier (which can In one embodiment, a Raman spectraispectrum poison 
control substance identification database can be generated detecting any change from a ‘Orma’ state). The 
and the in situ reading then thereto so that a method comprises the steps o f  (a) generating an excitation 
screening and assessment of the identity of which poison or 
poisons that the subject has been exposed can be readily 15 250); (b) focusing the excitation beam of said generating 
identified by matching the in situ reading to one or of step into the anterior chamber of an eye of the subject so that 
the pre-determined and digitally stored Raman spectra, The aqueous humor in the anterior chamber is illuminated (Block 
database of selected substances may be held on a central 260); (c) detecting a Raman spectrum corresponding to the 
database which can be remotely located or located at illuminated aqueous humor (Block 270); and (d) monitoring 
regional or selected locations (via the internet, intranet, or 20 the blood brain barrier dynamics based on the detecting step 
other communication means) and the localized reading can (Block 280). The detected Raman spectrum can indicate 
be uplinked to the larger database for a more comprehensive when or if a particular drug or analyte penetrates the blood 
screening. Alternatively, the signal processor or computer brain barrier (increases in quantity or becomes detectable) 
associated with the Raman excitationidetection device or when it normally travels in the vessels and/or either does not 
system may be configured with data corresponding to the zs penetrate the barrier or exists in a stable or predictable 
most common types of substances and if a localized scan amount in the eye (such as in the AH, VH, or vessel in the 
fails to match the in situ reading, a more comprehensive eye). The method may also include the step of exposing the 
computational screening can be performed off-line or at the subject to selected conditions during the focusing and 
remote or larger database location. detecting steps (Block 275). 
In certain embodiments, the monitoring step can be used 
invention is directed to an in vivo method for monitoring the to assess whether the dynamics thereof alter sufficiently to 
administration of a targeted therapy such as a drug, allow selected analytes, which would normally be inhibited 
chemical, gene, or other therapy, given to a subject for from traveling through the blood brain barrier, to pass into 
treatment of a condition in the brain (such as various cancers the intracranial spinal fluid through the blood brain barrier. 
or neurologie conditions). For example, the present inven- 35 This can be useful for clinical trials or assessments of new 
tion may be used during a treatment session using delivery drugs or treatment therapies. In other embodiments, the 
of a cytotoxic agent to treat a cancerous tumor in the brain monitoring step can be carried out when a person is under or 
(or to other patients for specialized drug treatments targeted exposed to extreme conditions such as when diving, flying, 
to the brain such as for treating neurological impairments in or mountain climbing, or when suffering from a traumatic 
the brain). The method includes administering a dose of a 40 head or brain injury, high stress, or the like. 
selected treatment agent (typically chemotherapy) to a sub- The method can also include the steps of comparing the 
ject (Block 200). The dynamics of the blood brain barrier are Raman spectrum from the detecting step to reference spec- 
deliberately or intentionally altered from the normal state trums corresponding to at least one selected analyte of 
(Block 210). The dynamics or functionioperation of the interest, and indirectly identifying the presence of the least 
blood brain barrier are monitored bv non-invasivelv obtain- 45 one analvte of interest in the subiect’s cerebral sainal fluid 
beam at a Of from 400 to 900 nanometers 
As shown in FIG. 13, another embodiment of the present 30 
ing the Raman spectrum of the aqueous humor (Block 220). 
A physiologically suitable non-specific marker, selected for 
its normal reluctance to cross the blood brain barrier, can be 
administered to the subject (Block 225), and the monitoring 
step can be carried out by identifying its presence in the 
selected region of the eye (typically in the AH, but the 
vitreous humor or “VH’ may also be suitable in certain 
embodiments). The non-specific marker can be synthetic or 
natural as noted (such as an antibiotic or conjugated billiru- 
bin or other suitable analyte). 
The dose of the (chemotherapeutic) agent delivered to the 
based on the detecting and comparing steps. 
FIG. 15 illustrates yet another embodiment of the present 
invention. This method for identifying an alteration in the 
blood brain barrier of a biological subject comprises the 
SO steps of  (a) non-invasively obtaining a first in vivo Raman 
spectrum of the aqueous humor of the subject (Block 300); 
(b) non-invasively obtaining a second in vivo Raman spec- 
trum of the aqueous humor of the subject (Block 310); (c) 
comparing the first and second readings (Block 320); and (d) 
ss detecting an alteration in the blood brain barrier (or the 
penetration or a particular drug or analyte) by comparing the 
brain can be estimated by determining the concentration in first and second Raman spectrums (Block 330). 
the AH (Block 230). The monitoring step can optionally be In another embodiment, shown in FIG. 16, a method for 
repeated a plurality of times during the administering step identifying an alteration in the blood brain barrier of a 
(Block 235). The blood brain barrier can be returned sub- 60 biological subject comprises the steps of  (a) non-invasively 
stantially to its normal state after a sufficient quantity of obtaining a first in vivo Raman spectrum of the AH of the 
(chemotherapeutic) agent has been delivered to the brain subject (Block 350); (b) obtaining a reference spectrum of 
(Block 240). The altering step can be carried out by admin- an in vitro sample representing the aqueous humor and 
istering a chemical which can be flushed from the system or comprising at least one selected analyte (Block 360); and (c) 
the dosing terminated to allow the normal function to return. 65 comparing the in vivo Raman spectrum to the reference 
In some embodiments, the non-specific marker can be the spectrum to identify an abnormality in the blood brain 
therapeutic agent itself. barrier (Block 370). The abnormality may be indicated by 
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detecting in the AH the presence of at least one selected 
analyte (typically one which is normally inhibited from 
passing through the blood brain barrier because of its 
molecular size or permeability and, as such, is not normally 
present in the intracranial fluid) thereby its presence in the 
AH also indicates its presence in the intracranial fluid of the 
subject. 
The at least one selected analyte can be one which 
typically does not cross the blood brain barrier so that a 
determination of its presence in the sample is indicative of 
connection having one or more wires, a portable computer 
diskette, a random access memory (RAM), a read-only 
memory (ROM), an erasable programmable read-only 
memory (EPROM or Flash memory), an optical fiber, and a 
s portable compact disc read-only memory (CD-ROM), a CD 
ROM, a DVD (digital video disk), or other electronic 
storage medium. Note that the computer-usable or 
computer-readable medium could even be paper or another 
suitable medium upon which the program is printed, as the 
i o  program can be electronically captured, via, for instance, 
an abnormality or impairment or successful intentional optical scanning of the paper or other medium, then 
alteration of the blood brain barrier dynamics. In one compiled, interpreted or otherwise processed in a suitable 
embodiment, the at least one selected analyte can be a manner if necessary, and then stored in a computer memory. 
bacteria. Computer program code for carrying out operations of the 
FIG. 17 illustrates an additional embodiment of the is present invention may be written in an object oriented 
present invention. In this embodiment, a reference library of programming language such as Java@, Smalltalk or C++. 
the profiles of the chemical peaks (chemical peak profiles However, the computer program code for carrying out 
can also include the chemical valleys or line shapes) of the operations of the present invention may also be written in 
Raman spectra signals of a plurality of substances can be conventional procedural programming languages, such as 
established or generated (Block 400). This can include 20 the “C” or FORTRAN programming language or even 
providing the chemical peak profiles for each of the plurality assembly language. The program code may execute entirely 
of the substances at different concentrations. A Raman on the user’s computer, partly on the user’s computer, as a 
spectrum signal can be obtained in vivo of the AH (or VH) stand-alone software package, partly on the user’s computer 
of the eye of a subject (Block 410). The chemical peak and partly on a remote computer or entirely on the remote 
profile of the in vivo obtained Raman signal can be deter- zs computer. In the latter scenario, the remote computer may be 
mined (Block 420). Next, the profile of the in vivo data is connected to the user’s computer through a local area 
compared to the reference library to see if there is a network (LAN) or a wide area network (WAN), or the 
statistical correlation (or best fit match) between one or more connection may be made to an external computer (for 
of the library profiles with the in vivo obtained profile example, through the Internet using an Internet Service 
(Block 430). If the answer is ves. then a list of one or more 30 Provider). 
, I  
substances can be generated with a percent correlation of the 
likelihood of the match (Block 440). The method may also 
rule out potential suspects (Block 441). The list is likely to 
include one or more substances, as many will contain 
chemicals with overlapping peaks, but the presence or 
absence of other peaks can help statistically fit the data to 
identify the closest matches. If there is no match, or the 
correlation percentage is below a certain threshold (such as 
below 20-50%), then the test can be identified as inconclu- 
sive (Block 450). The method may also allow a physician to 
query whether as suspect drug or substance is indicated, 
which may for example, consider whether a particular 
“suspect” substance which is believed to be the ingested or 
consumed poison may be in the subject. In turn, the method 
can respond to the inquiry to exclude the substance as a 
suspect with an identified statistical percentage (i.e., 95% 
confidence level that substance is not methanol) or to 
otherwise note the probability of this as the poison (i.e., 5% 
probability that the substance is methanol). 
As will be aaareciated bv one of skill in the art. the 
The present invention is described herein with reference 
to flowchart illustrations and/or block diagrams of methods, 
apparatus (systems) and computer program products accord- 
ing to embodiments of the invention. It will be understood 
3s that each block of the flowchart illustrations and/or block 
diagrams, and combinations of blocks in the flowchart 
illustrations and/or block diagrams, can be implemented by 
computer program instructions. These computer program 
instructions may be provided to a processor of a general 
40 purpose computer, special purpose computer, embedded 
processor or other programmable data processing apparatus 
to produce a machine, such that the instructions, which 
execute via the processor of the computer or other program- 
mable data processing apparatus, create means for imple- 
4s menting the functions specified in the flowchart and/or block 
diagram block or blocks. 
These computer program instructions may also be stored 
in a computer-readable memory that can direct a computer 
or other programmable data processing apparatus to function 
SO in a aarticular manner. such that the instructions stored in the 
I I  
present invention may be embodied as a device, method, or computer-readable memory produce an article of manufac- 
system comprising a digital processing system, and/or com- ture or output a test result including instruction means which 
puter program product. Accordingly, the present invention implement the function specified in the flowchart and/or 
may take the form of an entirely hardware embodiment or an block diagram block or blocks. 
embodiment combining software and hardware aspects. ss The computer program instructions may also be loaded 
Furthermore, the present invention may include a computer onto a computer or other programmable data processing 
program product on a computer-usable storage medium apparatus to cause a series of operational steps to be per- 
having computer-usable program code means embodied in formed on the computer or other programmable apparatus to 
the medium. Any suitable computer readable medium may produce a computer implemented process such that the 
be utilized including hard disks, CD-ROMs, optical storage 60 instructions which execute on the computer or other pro- 
devices, or magnetic storage devices. grammable apparatus provide steps for implementing the 
The computer-usable or computer-readable medium may functions specified in the flowchart and/or block diagram 
be or include, for example, but not limited to, an electronic, block or blocks. 
magnetic, optical, electromagnetic, infrared, or semiconduc- As is seen in FIGS. loa, b, c, FIGS. 5 and 6, the system 
tor system, apparatus, device, or propagation medium. More 65 5 includes a signal processor or controller 32s. The signal 
specific examples (a non-exhaustive list) of the computer- processor or controller can be a general purpose 
readable medium would include the following: an electrical microprocessor, a digital signal processor or a specific 
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purpose processor. The signal processor can be an electronic 
device, a software or program-implemented device running 
on a general-purpose computer, or combinations of such. 
The present invention should not be construed as limited to 
the particular configurations illustrated in the figures but is 
intended to encompass other configurations capable of car- 
rying out the operations and/or functions described herein. 
tigators. These animals had experienced experimental myo- 
cardial infarction 48 hours prior to euthanasia. They were 
sacrificed by rapid exsanguination under ketamine and xyla- 
zinc anesthesia, Aqueous humor samples were kept frozen 
until glucose levels could be measured and R~~~~ spec- 
troscopy performed. Glucose concentration was measured 
with a commercial glucometer ( ~ l ~ ~ ~ ~ ~ ~ ~ ~  ~ l i ~ ~ ,  B ~ ~ ~ ~ ,  
standards. Each measurement was repeated, and the average 
measurement was considered actual glucose concentration. 
quartz cuvettes designed 
to hold a volume of 80 PL and Permit direct optical access 
to the solution by the spectrometer without traversing glass 
walls Or CoversliPs. 
Raman spectroscopy was performed with a fi1.8 holo- 
graphic imaging spectrograph (Kaiser Optical Systems, Ann 
Arbor, Mich., USA) attached to an Olympus BX60 micro- 
scope with lox  objective, Data were collected using a 
Princeton Instruments (Trenton, N.J., USA) camera with a 
1024x256 CCD array (EEV, United Kingdom) cooled to 
the functionality of the data processing system or signal 20 -80” c. with liquid nitrogen. Illumination of the sample 
and memory. programmable memory Ti:Sapphire laser (Spectra Physics 3900S, Mountain View, includes, but is not limited to static RAM (SRAM), dynamic 
The processor 32s can be any commercially Elkhart, Ind,, USA) and confirmed against concentration 
Or microprocessor. The computer 32 Or 
data port(s) or other such devices that also 
processor or controller may include a data processing system 
with 
municate with the processor. The I/O data port can be used 
to transfer information between the data processing system 
or signal processor 32s and another computer system or a 
network (e.g., the Internet) or to other devices controlled by 
the processor. These components may be conventional com- 
ponents such as those used in many conventional data 
processing systems which may be configured in accordance 
with the present invention to operate as described herein. 
The devices Or the Present invention may include memory 
devices containing the software and data used to implement 
were placed in 
processor 32s. The memory can both programmable through the microscope objective was achieved with a 
pumped by an argon laser (Spectra Physics 
the 
Of 785.0 nm (30 
RAM (DRAM), flash RAM, EEPROM or other such pro- 
grammable memory devices whose contents may be modi- 
fied, The read only memory may be of a type which may not 25 
2010E). Spectrographic data was integrated 
was at a 
be modified after its initial programming, such as ROM or mW) for 10 seconds. This illumination was then repeated at 
PROM but may also be programmable in certain embodi- a 
ments of the present invention. The integrated spectra at the two slightly different wave- 
The memory may contain several categories of software lengths were then subtracted from one another. This effec- 
and data used in the data processing system or system 30 tively eliminates the broadband fluorescence, which does 
processor: the operating system; the inputioutput (IiO) not shift relative to the excitation wavelength. It leaves the 
device drivers; and the image (and/or in the case of dual Raman-shifted spectra appearing as a bipolar pattern (FIG. 
stimulus, the auditory) data. As will be appreciated by those 1). 
of skill in the art, the operating system may be any operating Multivariate analysis of the spectra was accomplished 
such 35 using Holograms (Princeton Instruments, Trenton, N.J.) and 
as os/2, Or from International Business Grams (Galactic Industries, Salem, N.H. USA) software 
Machines Corporation, packages. Thirty-two aqueous humor samples (from sixteen 
Of 787.2 nm. 
for use with a data Processing 
N.Y., WindowsCE~ 
WindowsNT, Windows95, Windows98 Or Windows2000 
from Corporation, Redmond, Wash., 
Linux, proprietary operating systems or dedicated operating 40 set’ Hence, the system trains On 
systems, for example, for embedded data processing sys- 
rabbits) were evaluated using a uround approach to 
iteratively group all but one of the samples into a training 
but One Of the samples, 
then rotates the 
from Palm, Inc., MacOS from Apple Computer, UNIX or 
estimates the glucose level in that 
terns. test sample into the training set. This cycle is repeated until 
The I/O device drivers typically include software routines 
accessed through the operating system to communicate with A back Propagation neural network (D. Rumelhart et al., 
devices such as the input devices, the display 25 (FIG. 7), the 45 Nature 323, 533 (1986)) was employed to determine if a 
I/O data port(s), and certain components of the memory. The nonlinear regression method would better predict the glu- 
data can be static and dynamic data used by the operating cose concentration from the Raman spectra of aqueous 
system, I/O device drivers, the detector, and other software humor. Such a model may compensate for as yet unknown 
programs that may reside in the memory. interactions between analytes in aqueous humor. A two-layer 
While the Present invention is described, for example, so back propagation neural network (Neuralware, Inc., 
with reference to particular divisions of programs, functions Pittsburgh, pa,, USA) was employed using a 
and memories, the present invention should not be construed function as the nonlinear element, ~~~t~~~ derived from the 
as limited to such logical divisions. Thus, the present inven- partial least squares algorithm served as the inputs to the 
not be construed as limited thereto as it is neural network. Raw spectral data could have been used but 
the linear regression preformed earlier, round robin training out the operations described herein. 
following non-limiting Examples, in which “Puu, and testing was utilized. During training, the neural net- 
microliters; “dL” deciliters, “mW” milliwatts, work’s weights were adjusted to minimize the total squared 
U ~ ~ X  nanometers, UK,X kilograms, “J” error between the actual glucose concentration and the 
~ ~ ~ l ~ ~ ,  u ~ ~ ~ x  square centimeters  and temperatures 60 predicted glucose concentrations. Each sample was tested 
are given in degrees Centigrade. using a neural network trained on the remaining 31 samples. 
have served as an unknown test 
intended to encompass any configuration capab1e Of carrying 55 would have required a prohibitively large training set, As in 
The present invention is explained in greater detail in the 
EXAMPLE 1 EXAMPLE 2 
Measurement of Aqueous Humor Glucose in Vitro Correlation of Aqueous Humor Glucose with 
with Raman Spectroscopy 65 Rising Blood Glucose 
Aqueous humor was obtained from sixteen New Zealand 
white rabbits within one minute of sacrifice by other inves- 
Nine female New Zealand white rabbits were used for this 
part of the study. They were anesthetized with ketamine (50 
US 6,961,599 B2 
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mg/kg) and xylazine (7.5 mg/kg) given as a single intra- EXAMPLE 4 
muscular injection. Xylazine blocks release of insulin from 
the pancreas and causes blood glucose to rise (K. Chalabi et Results for Correlation of Aqueous Humor Glucose 
al., Ophthalmic Res. 19, 289 (1987); J. Arnbjerg et al., with Rising Blood Glucose 
Ophthalmic Res. 22, 265 (1990)). The rate of rise of blood glucose after xylazine injection 
Blood samples were taken from the central ear arteries at is highly variable from animal to animal (FIG. 3). In fact, in 
various times following the injection of anesthetic once the one rabbit there was little change in the blood glucose 
animals were adequately anesthetized. Whole blood was concentration over time. 
immediately measured for glucose concentration with a If only samples taken in the first fifteen minutes after 
commercial glucometer (Glucometer Elite, BaYer). In most lo anesthetic injection are considered, aqueous humor glucose 
instances two measurements were made. The average mea- concentration is higher than blood glucose concentration 
surements are reported. If the measurements differed by (207+28 mg/dL for aqueous humor; 135+27 mgidL for 
more than 20%, a third measurement was made. If one blood). When calculated blood glucose rises above 200 
measurement differed by more than 20% from the mean, it mg/dL, simultaneous aqueous humor glucose parallels blood 
was discarded. In instances when blood glucose concentra- 1s glucose nearly linearly [aqueous humor glucose=1,18 (blood 
tion appeared stable, occasionally only one measurement glucose)-72,7; r2=0,88] (FIG. 4). 
was made. The number of aqueous humor samples from second 
At various times after induction of anesthesia, samples of paracenteses was insufficient to draw conclusions about their 
aqueous h m ~ o r  were taken. This was done by Paracentesis significance. They did not appear, however, to correlate well 
with a 25-gauge needle through clear cornea near the limbus 2o with aqueous humor glucose levels from initial paracenteses 
after administration of proparacaine eye drops. Aqueous (FIG. 4). 
humor glucose concentration was measured with the glu- These data indicate that the baseline ratio of aqueous 
cometer in a manner similar to the blood. humor glucose to blood glucose in rabbits is approximately 
In rabbits, there is massive b ~ ~ ~ k d o w n  of the blood- 1.5. (It may actually be higher than this as a true baseline 
aqueous barrier after a single paracentesis of the anterior 2s was not obtained, and the blood glucose levels were likely 
chamber of the eye (w. Unger et al., ExP. Eye Res. 20, 255 elevated by the time the first samples were obtained, even in 
(1975)). The aqueous humor becomes too Viscous for repeat the first 15 minutes after injection.) This is much higher than 
Paracentesis for at least 30 minutes. Consequently, the in humans and higher than in previous reports on rabbits. All 
results are reported for the first Paracentesis of an eye. In a 3o previous reports on rabbits, however, were prior to recog- 
few instances, however, a second Paracentesis was made an nition of the hyperglycemic effect of xylazine anesthesia, yet 
5 
hour later to assess how the breakdown of the blood-aqueous 
barrier may have affected the correlation of aqueous glucose 
many of them used xylazine anesthesia, In addition, most 
previous reports assumed that the rabbits were at steady- 
with plasma glucose. state euglycemia, without actually confirming that this was 
Average blood glucose concentrations for each animal 3s the case. These facts may account for some of the highly 
were plotted against time after anesthetic injection. Since it variable results in previous reports. 
was not possible to obtain blood samples simultaneous with These data also demonstrate that aqueous humor glucose 
aqueous humor samples, a best-fit SeCOd-Order PolYnomial in the rabbit responds almost immediately once blood glu- 
was calculated for each animal. This was used to calculate cose exceeds 200 mg/dL, m e  relationship of aqueous humor 
the blood glucose concentration at the time that the aqueous 4o glucose to blood glucose is nearly linear while blood glucose 
hwmr sample was taken. Aqueous glucose concen- is rising above 200 mg/dL. Below that level, aqueous humor 
tration was then plotted against the calculated simultaneous glucose appears stable, What happens to aqueous humor 
blood glucose concentration for all animals. DeltaGraPh glucose when blood glucose is clamped at a hyperglycemic 
software (Delta Point, Inc., MontereY, Calif. USA) was used level, or when blood glucose concentration drops, has yet to 
for all statistical calculations. 4s be determined. Nonetheless, equilibration of aqueous humor 
glucose with blood glucose probably occurs within minutes EXAMPLE 3 
in rabbits. If rapid equilibration of aqueous humor glucose 
Results for Measurement of Aqueous Humor also occurs in humans, it could serve as an excellent 
Glucose in Vitro with Raman Spectroscopy substrate for non-invasive glucose monitoring. 
Previous investigators have found no breakdown in the 
fluorescence peaks that obscure the underlying Raman sig- blood-aqueous barrier of albino rabbits exposed to infrared 
nature (FIG. 1). When the spectra from the two slightly radiation with energy densities up to 106 J/cm (D. Reddy, 
different wavelengths are subtracted, one from the other, the supra; G. Peyman et al., Exp. Eye Res. 42, 249 (1986); T. 
Raman shifted spectra become apparent as bipolar peaks. Kurnik et al., Znv Ophthalmol. vls. Sci. 30, 717 (1989)). 
Actual aqueous humor glucose concentration, measured ss Infrared energy densities as low as 44 J/cm2 may be SUE- 
by the glucometer, ranged from 37 to 323 mg/dL in the cient to breakdown the blood-aqueous barrier in pigmented 
thirty-two samples. Multivariate analysis of the raw spectra rabbits, however. This is still substantially higher than the 
from these samples with the partial least squares algorithm energy density that would need be applied with the Raman 
revealed fair correlation (r2=0.76) between the predicted technique disclosed herein. 
aqueous humor glucose concentration and the actual con- 60 FIGS. 21A-C illustrate experimental results obtained for 
centration. Multivariate analysis of the subtracted spectra (a) the spectrum for an artificial in vitro AH in a model 
from these samples with the partial least squares algorithm anterior chamber (FIG. 21A); (b) the spectrum for an actual 
resulted in improved correlation (r2=0.90) between the pre- in vitro measured (extracted real AH) in a model anterior 
dicted aqueous humor glucose concentration and the actual chamber (FIG. 21B); and (c) the spectrum for an actual in 
concentration. When back propagation with an artificial 65 vivo AH measurements (FIG. 21C). A 20x objective with a 
neural network is further applied to the data, correlation is numerical aperture of about 0.4 was used to obtain the data. 
excellent (r2=0.98) (FIG. 2). The “ensemble” spectra (of the constituents of the AH) 
The raw spectra of rabbit aqueous humor show broad 50 
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correspond well between the three figures. As may be 
expected, the in vivo and in vitro intensity of the Raman 
spectra was less than the in vitro artificial sample, but the 
spectra peaks corresponded well between the measurements 
(the device able to detect the physiological levels). The in 
vitro measurements of the AH were obtained using extracted 
rabbit eyes placed under a contact lens. 
EXAMPLE 5 
Measurement of the Integrity of Blood-Aqueous and Blood- 
Brain Barriers 
The blood-brain and blood-aqueous barriers block pas- 
sage of large molecules into the cerebrospinal fluid or 
aqueous humor. Many drugs and disease processes result in 
disruption of both the blood-aqueous barrier and the blood- 
brain barrier. In the case of such drugs or disease processes, 
disruption of the blood-brain barrier can be inferred from 
breakdown of the blood-aqueous barrier. Breakdown of the 
blood-aqueous barrier can be measured by measuring the 
protein content of the aqueous humor or by measuring the 
concentration of other substances (e.g., drugs) within the 
aqueous humor. Such substances may be quantifiable by 
Raman spectroscopy and the protein can be calculated from 
the fluorescence spectrum since the fluorescence spectrum is 
largely generated by protein. Consequently, the devices 
disclosed herein for measuring glucose and other Raman 
scattering metabolites in the eye can be used for measuring 
the integrity of the blood-aqueous and blood-brain barriers. 
Raman scattering molecules of different sizes that do not 
normally cross the blood-aqueous or blood-brain barrier 
could be administered to a patient intravenously. The pres- 
ence of these molecules is then identified and/or quantified 
by Raman spectroscopy of the anterior chamber of the eye. 
This can be used to determine the size of molecules which 
pass through the blood aqueous barrier. The signature of the 
Raman spectroscopy signal can then digitally be compared 
to reference signals (without requiring the use of a difference 
methodology which would subtract the amount of fluores- 
cence to reveal the Raman spectra of these substances) with 
the device disclosed herein would reflect the passage of 
natural proteins through the blood-aqueous and blood brain 
barriers. 
Therapeutic drugs can also be measured to determine their 
effectiveness in crossing the blood-aqueous or blood-brain 
barrier or to determine if a drug has undesirable passed 
therethrough. 
EXAMPLE 6 
Monitoring the Blood Brain Barrier During a Treatment 
Session 
Apatient undergoing treatment for a cancer located in the 
brain or on the other side of the blood brain barrier is 
administered a non-specific marker which is configured such 
that it does not normally cross the blood brain barrier (or is 
reluctant to do so) and which is relatively easily detectable 
when in the AH by the use of Raman spectroscopic analysis. 
The blood brain barrier can be altered by administering an 
osmotic agent such as a chemical substance (such as a drug 
identified by the trade name "MANNITOL" or a similar 
substance) which acts to physiologically alter the blood 
brain barrier. In so doing, the blood-aqueous barrier is also 
altered. In turn, the non-specific marker travels to the AH. 
An optical measurement can be obtained to confirm that the 
non-specific marker is indeed in the AH (in a sufficient or 
elevated quantity to indicate that the blood-aqueous barrier 
has been altered). The present invention, recognizing that 
the mechanics of the blood-aqueous barrier and the blood- 
brain barrier are similar, then presumes that the blood brain 
42 
barrier has also been altered sufficiently (scale correlation 
factors may be applied to assure that the blood brain barrier 
is openedialtered a sufficient amount). 
A therapeutic drug (which may be a chemotherapy or 
5 cytotoxic drug) can then be administered (injected or oth- 
erwise delivered) to the subject. Administering the thera- 
peutic drug after the barrier has been altered can help ensure 
that the therapeutic drug is not introduced until the blood- 
brain barrier is altered sufficiently and can allow an elevated 
amount of the therapeutic drug to pass through the blood- 
brain barrier over a non-altered state. This can facilitate that 
more of the drug goes where it is targeted and can reduce the 
amount in the system of the subject which can often be 
exposed to undesirable amounts of cytotoxic drugs in con- 
ventional treatments in order to ensure that a sufficient 
amount actually reaches the tumor. 
Thus, the present invention now allows one to intention- 
ally break down the barrier and non-invasively confirm the 
alteration before delivering medicines, which do not nor- 
mally readily cross the blood brain barrier, to tumors and the 
like positioned in the blood aqueous or blood brain barrier. 
Correlations of the amount of the drug administered to the 
subject, to the amount of the marker administered and 
detected in the AH, may be established to allow an estimate 
of the amount of the drug in the spinal fluid or in the blood. 
Thus, the present invention may also be able to titrate the 
dose so that the levels in the spinal fluid are sufficiently high 
but not toxic to the patient in non-targeted regions of the 
body. 
Measurement of Brain Alcohol Level 
A portable device can be used to hold the optical genera- 
tion and measurement system. The device can be readily 
carried by police enforcement agencies and conveniently 
3s used when a suspect is evaluated for potential DUI infrac- 
tions. Thus, the device can be positioned over the eye(s) of 
the subject and the subject can be instructed to read or 
identify the text or object encoded or displayed as the 
fixation target in the headset over the eye or eyes. When the 
40 subject verbally affirms the proper identification of the 
fixation target, the device can be operated to obtain a 
reading. The device may include an auto or manual focus to 
correct the vision in the device and to allow the subject to 
focus to the target as needed. Almost instantaneously, the 
4s police officer can have quantitative results of the brain 
alcohol or blood alcohol level of the suspect. The amount or 
concentration of the alcohol determined to be in the AH (or 
conjunctiva vessel) can be correlated to either a blood 
alcohol and/or brain alcohol level. Many states presently 
SO regulate blood alcohol levels; however, it is anticipated that 
an impairment can be assessed also based on either or both 
blood or brain alcohol levels. As such, the device may 
generate a plurality of numbers, such as the concentration in 
the eye, and, the indirectly measured or correlated concen- 
ss tration in the blood and/or brain. If above the legal limit, 
which can be programmed for each state or locality, a 
documentary arrest record can be generated with a date and 
time stamp encoded onto the measurement record that can 
be automatically generated and electronically stored or 
In some embodiments, the Raman spectrum of the subject 
may include many wavelengths and the determination of the 
concentration or presence of alcohol may include determin- 
ing the significant peaks associated with alcohol and sub- 
65 tracting the AH constituents from the signal. It is anticipated 
that the method and devices will be able to identify blood 
alcohol and brain alcohol levels between about 0.001-1%, 
10 
1s 
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30 EXAMPLE 7 
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and typically between 0.01-0.8% (noting that concentra- The present invention can also be used to screen athletes 
tions above 1% may be lethal) and that medical assistance for banned substances prior to competitions or at periodic or 
may be indicated for certain levels. audit intervals, and/or to screen parolees for violation of 
EXAMPLE 8 parole. Indeed, the readings can be obtained locally and then 
~ ~ ~ - i ~ ~ ~ ~ i ~ ~  in vivo Identification of the presence of s electronically relayed to a remote monitoring station where 
Illegal Narcotics the results can be analyzed and proper authorities alerted of 
Aportable device can be used to hold the optical genera- a positive test. 
EXAMPLE 10 tion and measurement system. The device can be readily 
Identification of Ingested Poison(s) carried by state or federal police enforcement agencies (or hospitals including medical examiners for autopsy) and i o  
conveniently used when a suspect is evaluated for potential 82 an in situ reading can be taken On 
configured as a headset with the display and light transmis- medic at a home or in route to a hospital, or by a clinician, 
sion path positioned in front of the eye(s) of the subject. The such as at an Emergency Room, to fast 
subject can be instructed to read or identify the text or object triage assessment Of whether One Or more Poisons are 
encoded or displayed in the device as the fixation target in Present in the body. One reading may be able to identify one 
the headset Over the eye or eyes, The device may include an or more of several different signature peaks associated with 
auto or manual focus to correct the vision in the device and several different poisons. The poisons may be common 
to allow the subject to focus to the target as needed. When household products such as different medications, or a 
the subject verbally affirms the proper identification of the 2o pesticide/herbicide, a cleaning agent, or antifreeze. By pre- 
fixation target, the device can be operated to obtain a evaluating the Raman signature of a plurality of common 
reading. Almost instantaneously, the police officer can have substances and electronically storing the data associated 
quantitative results of whether the suspect has inhaled, therewith in an electronic poison control reference library, 
ingested, injected, or otherwise consumed an illegal nar- the methods and devices of the present invention can decon- 
cotic. It is anticipated that concentrations in the range of volute the in situ obtained Raman spectrum signal to build 
between about 0,001-1% (in the AH) or higher in the or match a signal pattern with the Raman reference stan- 
conjunctiva vessel (i.e., in the blood volume) may be quan- dards. Based upon the substances with signatures, which 
tified. Drugs present in small quantities (such as the pico- substantially match the in situ Raman signal, probable or 
molar range) may be able to be identified (or the bodies' possible substances can be identified (or to exclude other 
reaction thereto identified thereby identifying the drug) but 3o suspect substances). Knowing which of the chemicals or 
may not be able to be reliably quantified. substances have the profile signature closest to the in situ 
It is noted that illegal narcotics may vary jurisdiction to obtained signature, the Raman signal(s) allows for the 
jurisdiction and the device can be programmed according to identification of which poisons may be in the body. The 
the laws of the jurisdiction of use. Examples of illegal match can be based on a computational comparison of peaks 
narcotics include opiate-based drugs such as cocaine in 3s or a graphical comparison. For example, the match can be 
several forms such as crack, powder, and the like, and other carried out by matching the peaks or line shape profile across 
drugs such as LSD, pcp, angel dust, marijuana, and others. the spectrum of interest via best-fit curves or statistical 
It is anticipated that the most commonly used or street correlation methods can identify products which align or 
available illegal drugs or abused prescription drugs can be match that of the data from the subject. A list of substances 
analyzed to predetermine the Raman signature as discussed 4o with associated probability ratings can be provided to the 
above and these reference signature standards for these clinician. 
substances stored for reference to the in situ reading In addition, a quantitative determination of the amount of 
obtained on the suspect. the identified substance or substances in the body may be 
In certain embodiments, the device and method can able to be made depending on the strength of the signal 
include assessing both, the brain alcohol (or blood alcohol) 4s (stronger signals typically indicate higher concentrations). 
level of the suspect, and the presence of an illegal narcotic In one embodiment, the Raman signature of a selected 
with one reading. Further, the present invention can be used metabolite can be reviewed to see if the level is carcinogenic 
to develop legal limits for other non-alcohol products so as in the subject. For example, antifreeze (ethylene glycol) can 
to ascertain whether an individual is impaired for improved be toxic to the liver. If it is identified that the either ethylene 
glycol was ingested or that the liver is emitting toxins or safety on the roadways. 
If an illegal narcotic is identified or if the alcohol level is products, a treatment such as alcohol can be administered to 
above the legal limit, (the legal limit can be programmed for offset the toxicity of the poison. Similarly, for other 
each state or locality), a documentary arrest record can be embodiments, the substance or drug itself may not be 
generated with a date and time stamp encoded onto the detectable in minute quantities in the body (typically in the 
measurement record which can be automatically generated pic0 or micro molar range). However, it may be possible to 
and electronicallv stored or minted. detect either a constituent of the substance of interest, or a 
to 
illegal possession of drugs, In operation, the device can be an Of a poison suspect, either by a para- 
a 
2s 
so 
5s 
physiologic reaction to the substance, to see if it is in an 
elevated level in the body (due to the body breaking down EXAMPLE 9 Determination and/or Identification of Drug or Steroid Use or reacting to the substance). In lieu of conventional urine tests, the present invention 
can be used to screen potential employees for drug use, or 60 EXAMPLE 11 
to assure employees are drug or alcohol free prior to Identifying a Pre-determined Substance Using Resonant or 
allowing them to operate equipment (such as airplanes, Strongly Pre-resonant Raman Spectra and/or Double Bond 
trains, buses, subways, or other mass transit systems or Peaks in the Raman Spectrum 
heavy equipment and the like). This convenient and non- In certain embodiments, the excitation wavelength of the 
invasive screening may be a suitable testing system to help 65 substance of interest is selected so that it amplifies the 
assure that the operators entrusted with the lives of others are detectable RR response signal or spectra. The excitation 
not operating in an impaired state. wavelength is selected so that it lies within or proximate to 
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the absorption spectrum of the selected substance. The RR 
spectra is typically generated by a wavelength that resides 
within the absorption spectrum (and above 400 nm). As 
noted above, the term “resonant Raman” includes non- 
resonant excitation wavelengths approaching the absorption 
spectrum that can be used to generate spectra with increased 
signal strength (such as signal strengths having 100-1000 
times or more signal intensity strength relative to excitation 
wavelengths that substantially depart from the wavelengths 
associated with the RR spectra). One or more peaks of 
interest in the RR spectra can be monitored to identify the 
presence and/or quantity of the substance in the subject. In 
particular embodiments, a chemical shift peak associated 
with a double carbon bond may be monitored. 
In certain embodiments, one or a plurality of selected 
segments (typically relatively narrow regions of less than 
about 200 cm-’, and more typically less than about 100 cm-I 
in width) in the Raman spectrum can be used to determine 
the concentration levels in a subject. The regions used to 
assess concentration can be selected so as to exclude regions 
that are associated with spectral shift that may occur at 
increased concentration levels to thereby provide reliable 
concentration data over a broader in vivo range of probable 
bio-concentrations. 
FIG. 22A illustrates the chemical structure of a chemo- 
therapeutic agent known as fenretinide (4-HPR), and shows 
a conjugated chain structure portion of the structure that 
permits resonance enhancement. Note that even at 
10-micromolar concentration the solution has a yellow 
color. This can be important because the concentration may 
be such that the drug can block the penetration of the 
excitation light and limits the Raman scattering (e.g., see 
FIG. 26). Typically, at lower concentrations this is not a 
problem. 
FIG. 23 is a graph of the absorption spectrum of 
fenretinide, illustrating that the absorption peaks at 365 nm. 
Exciting the molecule at 406.7 nm enhances the signal such 
that most of Raman shifted scattered light is not absorbed by 
the molecule itself, and so that undesirable excitation or 
exposure wavelengths are avoided (such as those below 
e400 nm). 
FIG. 24 is graph of the Raman spectrum of intensity 
verses wavelength shift of a non-resonant Raman spectros- 
copy (using an excitation wavelength of 785 nm) of fenre- 
tinide (concentration 10 mM, dissolved in ethanol). The 
spectrum shows key peaks of fenretinide as distinct from 
those of ethanol (ETOH Peak at 881 cm-I). Particular peaks 
of interest for the fenretinide one or more of which may be 
monitored (or the entire profile) include the peak at 1171 
cm-I (corresponding to the carbon-carbon bond) in the 
molecular structure and the peak at 1576 cm-I 
(corresponding to the carbon to carbon (double bond)) in the 
molecular structure. 
FIG. 25A is a graph of the absorption spectrum 
(absorption versus wavelength) of a solution of 10 mM of 
fenretinide. FIG. 25A is inset within FIG. 25B, which is a 
graph of pre-resonant (excitation wavelengths above the 
resonant wavelength) spectra of a 10 mM fenretinide cor- 
responding to the substance with the absorption spectrum 
shown in FIG. 25A. As shown, the intensity is normalized to 
the ETOH signal (arbitrary units), but the data need not be 
adjusted in this manner. Three different excitation wave- 
lengths are shown, the signal strength increasing for a 
decreasing wavelength. That is, the spectra corresponding to 
the 514 nm excitation wavelength has a larger signal inten- 
sity than the spectra corresponding to either the 633 nm or 
785 nm wavelengths. As shown, the intensity values of the 
46 
peaks at 1576 cm-I and 1171 cm-I are increased relative to 
the peaks at these positions in the Raman spectra for the 785 
nm or 633 nm excitation wavelengths. Accordingly, FIG. 
25B demonstrates that Raman sensitivity increases as the 
5 excitation wavelength approaches the absorption spectrum 
of a particular molecule or substance (shown for illustrative 
purposes as fenretinide, even at pre-resonance wavelengths). 
This may be useful in that devices can be configured to 
operate above resonance wavelengths (outside the absorp- 
tion spectrum or curve) although approaching absorption 
spectrum values and may be particularly suitable for detec- 
tion of the peaks due to carbon double bonds that occur even 
for chemicals that do not resonate or for which resonant 
Raman spectroscopy would be difficult. 
FIG. 26 is a graph of resonant Raman (RR) spectra of 
fenretinide generated at an excitation wavelength of about 
406.7 nm. The peaks for fenretinide at 117licm and 15761 
cm can be detected at concentrations as low as 0.1 micro- 
moles. The peaks (S) from the solvent, ethanol, are dimin- 
ished at the higher fenretinide concentrations due to the 
absorption of excitation light by the fenretinide itself. 
FIG. 27 is a drawing of the chemical conjugated structure 
of amphotericin B (C,,, H,,, NO,,), an exemplary antifun- 
gal agent. This agent is a broad-spectrum antifungal agent 
used to treat potentially fatal fungal infections of the CNS. 
It has a molecular weight of 924.1. 
FIG. 28 is a graph of the absorption spectrum of ampho- 
tericin B at a concentration of 5 pgiml. 
FIG. 29 is a graph of the RR spectrum of (generated at an 
3o excitation wavelength of 406.7 nm) of amphotericin at three 
different concentrations (mixed in MeOH): 5.0 pgiml, 0.5 
pgiml, and 0.05 pgiml. Characteristic peaks of amphotericin 
can be detected by Resonant Raman (RR) spectroscopy (406 
nm) at concentrations as low as 0.05 microgramsiml (and 
3s potentially much lower). The therapeutic level of amphot- 
ericin is about 0.5-5.0 microgramsiml. 
EXAMPLE 12 
Non-Invasive Ethanol Monitoring Using Raman Spectros- 
COPY 
Raman-based instruments and information processing 
capability can be used to non-invasively measure ethanol 
and/or its metabolites in the human aqueous humor. 
It is anticipated that the ability to measure ethanol non- 
invasively may revolutionize the treatment and study of 
4s alcoholism. Conventional techniques that measure ethanol 
by electrochemical, enzymatic, or colorimetric techniques in 
the breath, urine, or excreted body fluids are generally 
considered intrusive, unreliable, or subject to user non- 
compliance. Spectroscopic techniques have been proposed 
SO in the past, but the techniques remain elusive. See, e.g., 
Marose S, Lindemann C, Ulber R, Scheper T. Opticalsemov 
systems for biopvocess monitoring, Trends in Biotechnology 
In pilot studies undertaken in connection with the present 
ss invention, a correlation of ethanol concentration predicted 
by Raman spectroscopy with actual ethanol concentration in 
aqueous solution at levels typically found in blood following 
alcohol consumption has been demonstrated. Metabolites of 
ethanol, such as acetaldehyde and acetate, may be measured 
60 non-invasively, allowing for the added benefit of studying 
alcohol metabolism. 
In the past, non-invasive spectroscopic detection of alco- 
hol has been problematic because blood, tissue, and most 
excreted fluids contain numerous substances that confound 
65 ethanol spectral signatures. Appropriate selection of sources 
or techniques for spectroscopic analysis can inhibit or sup- 
press these confounding signatures. One suitable monitoring 
10 
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site/source is the aqueous humor (AH) filling the anterior rabbits, Diabetes Tech. and Therapeutics. 2:141-151, 1999. 
chamber of the eye (between the lens and cornea). The AH An existing external cavity diode laser manufactured by 
contains relatively few molecules (such as proteins) capable SDL can be utilized as the excitation source. An excitation 
of interfering with the spectroscopic detection of ethanol. wavelength of 785 nm may be selected because it is barely 
The primary constituents of AH are glucose, lactate, 5 visible to the subject and provides a comfortable fixation 
ascorbate, and urea. Accurate and reliable measurement of target as well as a Source which may be used in a minimah' 
these metabolites at physio~ogic levels is possible with or non-intrusive continuous monitoring device. Near- 
fluorescence from the eye as well as from minor constituents described in the specification above in more detail. within the aqueous humor. However, Raman scattering Furthermore, as with cerebrospinal fluid, AH can be i o  efficiency decreases inversely with wavelength to the fourth substantially freely permeable to ethanol. This fact and its power, This decrease in Raman signal associated with near- 
optically accessible location make AH a suitable choice as a infrared excitation can be by using a liquid 
site for non-invasive analysis of ethanol. In addition, Raman nitrogen cooled, thick-epitaxial, deep depletion CCD detec- 
by or linked to an identify-verification device that identifies 15 700-1000 nm wavelength range (typically about 785 nm), 
individuals based on an image analysis of retinal or iris since the silicon CCD becomes increasing transparent in the 
architecture. Examples of biometric evaluations of the eye NIR, a thick-epitaxial design can reduce the effects from 
using retinal or iris structures include U.S. Pat. Nos. 5,291, etaloning. The REAsystem can employ a confocal configu- 
560; 6,119,096; 5,615,277; 5,613,012; 5,572,596; 5,471, ration for the eye, which allows for selective collection of 
203; 5,336,970; the contents of these patents are hereby 20 spectra from the aqueous humor of the eye as well as for 
Raman spectroscopy using reasonably low power levels as infrared excitation greatly reduces the background 
EthanolAssay (REA) Of the aqueous humor can be Obtained tor with high or extremely high quantum efficiency in the 
incorporated by reference as if recited in full herein. Such 
dual-purpose devices can be used for public safety or 
security purposes (such as analysis of drivers, pilots, work- 
ers in certain industries or for verifying the identify of an 
athlete, and the like). One manufacturer of iris-based bio- 
metric devices is IriScan, Inc., located in Mt. Laurel, N.J. 
The present invention can be embodied in portable 
devices that can obtain the signals from the eye(s) of a 
subject (for AH) sampling at desired field locations. For 
example, the image or signal acquisition can be carried out 
monitoring of centration of the beam. 
A diagram of examplary probe head architecture is shown 
in FIG. 6. As shown, the probe-head design incorporates a 
single-mode excitation fiber and a step-index multi-mode 
zs collection fiber. The probe-head objective images the focal 
point to the multi-mode collection fiber. A50 micron chrome 
aperture was evaporated onto the end of collection fiber to 
adjust the confocality of the probe head to collect as much 
Raman scattered light from within the anterior chamber as 
30 possible while rejecting light from the cornea or lens of the 
with a miniaturized device such as one that can be attached eye. A system configured in this manner was tested for its 
to headgear or face gear such as spectacles, goggles, face- ability to collect the spectra of saline by placing this solution 
mask, or a contact lens device. The signal acquisition device under a contact lens resting on a quartz plate. The signature 
that generates the REA of the aqueous humor can be of the contact lens, saline, and quartz plate could each be 
operated in an intermittent, semi-continuous, or even poten- 35 isolated by focusing on each element of this physical model 
tially in a low power continuous manner. REA of the 
aqueous humor has an advantage of being operable in a 
completely non-invasive manner. As such, it may be oper- 
able for intermittent rapid determination of ethanol alcohol 
levels at a particular point or points in time or as a longer- 
term monitoring device that collects data over a desired 
monitoring period of hours, days, or, even months. The data 
can be collected and analyzed by the (preferably portable) 
device itself or stored and telemetrically or periodically 
downloaded to a remote analvsis svstem. 
of the anterior chamber. This experiment was repeated on 
the eye of a living rabbit and similar results were obtained. 
See Lambert et al., Measurement of Aqueous Glucose in a 
Model Anterior Chamber Using Raman Spectroscopy, Jnl. 
40 Of Raman Spectroscopy (In Press, 2002). Spectra for both 
experiments are shown in FIGS. 31A and 31B. 
FIG. 31A illustrates the Raman spectra of artificial aque- 
ous humor (AAH) and components of a physical model of 
the anterior chamber collected using confocal optics. FIG. 
45 31B illustrates the in vivo Raman saectra of structures of the 
i d  
In certain embodiments, one or a plurality of selected anterior chamber of a rabbit. Raman spectra of AH can 
segments (typically relatively narrow regions of less than clearly be distinguished from those of nearby cornea and 
about 200 cm-l, and in certain embodiments less than about lens. 
100 cm-I in width) in the Raman spectrum can be used to Mathematical Models for Calculating Analyte Concentra- 
determine the ethanol concentration levels in a subject. The SO tion from Measured Spectra 
regions used to assess concentration can be selected so as to A variety of chemometric methods have been developed 
exclude regions that are associated with spectral shift that to derive quantitative information from the spectrum of an 
may occur at increased concentration levels to thereby aqueous test sample having a mixture of constituents. In 
provide reliable concentration data over a broader in vivo general, chemometric models are developed using Raman 
range of probable bio-concentrations. ss spectra acquired from a set of training samples where the 
Exemplary Raman Instrument for Spectral Measurements of concentration of one or more of the constituents in each 
AH sample is known. Calibration models are developed and 
The REA of aqueous humor can utilize an existing fi1.8 subsequently used to predict the concentrations of the con- 
Kaiser Optical Systems holographic imaging spectrograph stituents within sample unknowns for which these models 
which is fiber-optically coupled to a probe head that is 60 were developed. A summary of the commonly used linear 
configured to detect in a continuous or intermittent manner. methods is presented below. Review articles are available 
The probe head may be handheld, or mounted on a trans- which discuss these methods in detail. See, e.g., Geladi et 
lation stage for studying sedated animals. In the past, a 20x al., Partial least squares regression: A tutorial, Analytica 
objective was used to acquire spectra of 50-100 pL samples Chimica Acta. 1986, 185: 1-17; and Haaland et al., Partial 
of rabbit aqueous humor with excellent results in measure- 65 least squares methods for spectral analysis. Relation to 
ment of glucose, lactate, and urea. See Borchert et al, A other quantitative calibration methods and the extraction of 
non-invasive glucose monitor: Preliminary results in qualitative information, Anal. Chem. 1988: 60; 1193-1210. 
US 6,961,599 B2 
49 50 
The vast calibration models developed to date are linear mixture of glucose, lactic acid, and creatinine ranging in 
and therefore implicitly assume that the Beer-Lambert law is concentration from 0 to 66 mM. See Berger et al., An 
valid for the samples being utilized on the training or test set. enhanced algorithm for linear multivariate calibration, 
The Beer-Lambert law states that there must be a linear Anal. Chem. 1998; 70: 623-627, the contents of which are 
relationship between the concentrations of the constituents s hereby incorporated by reference as if recited in full herein. 
and the amount of Raman light scattered at a given wave- PLS and HLA were used to predict glucose levels in 
length from each constituent. For any given sample the whole blood and serum with reasonable success with a 
observed Raman signature is a linear combination of the standard error of prediction (SEP)=21 mg/dL for PLS and 
spectra of its constituents. The Beer-Lambert law may not be SEP=17 mg/dLfor HLA. See Berger et al., Multi-component 
valid when constituents react with each other or when they i o  Blood Analysis by Near-Infrared Raman Spectroscopy, 
interact with the solvent. For example, some of the Raman Applied Optics, 1999: 38: 2916-2926, the contents of which 
peaks for ethanol in aqueous solution shift as the concen- are hereby incorporated by reference as if recited in full 
tration of ethanol is increased. However, at concentrations in herein. 
the range of interest (5-500 mgidL), this effect is smaller PLS and/or HLA can be used as linear models to solve for 
than the resolution of most Raman instruments (5 cm-I). is the concentration of ethanol in a selected region in the eye, 
Even for high concentrations of ethanol, selected regions of such as in the aqueous humor. Both PLS and HLA calibra- 
the spectra in which the spectral shifts occur may be tion models are likely to perform well in predicting certain 
excluded from analysis to maintain the validity of the linear substances, such as, but not limited to, ethanol, in physi- 
model. ological fluids. PLS can be extended to solve for additional 
Alternatively, a piecewise linear calibration model can be 20 analytes by applying it separately for each analyte of inter- 
developed over several concentration ranges, where the est. HLA may be extendable algorithmically to include 
Beer-Lambert law remains valid over each range. Generally multiple pure spectra (e.g. ethanol, acetaldehyde, and 
stated, linear chemometric methods can be divided into two acetate) within an enhanced calibration model for the analy- 
types of algorithms: explicit and implicit methods. Explicit sis of complex mixtures. 
methods are mathematical models that employ knowledge of zs Notwithstanding the above, as before, in certain 
the spectra of every constituent. Explicit methods include embodiments, the model can analyze one, and typically a 
linear regression, classical least squares (CLS) and ordinary plurality of selected segments (typically relatively narrow 
least squares (OLS). These methods are generally capable of regions of less than about 200 cm-’, and more typically less 
producing superior calibration models. However, significant than about 100 cm-’ in width) in the Raman spectrum can 
performance degradation can occur if a constituent is omit- 30 to determine the concentration levels in a subject. The 
ted from the calibration model or in the presence of spectral regions used to assess concentration can be selected so as to 
artifacts such as baseline shifts. Employing explicit methods exclude regions that are associated with spectral shift that 
in complex biological fluids such as aqueous humor can be may occur at increased concentration levels to thereby 
difficult in general, since many constituents may be provide reliable concentration data over a broader in vivo 
involved. To generate a reliable calibration model using 3s range of probable bio-concentrations. 
these techniques, a chemical assay of each and every con- In Vitro Raman Ethanol Assay of “Artificial” Aqueous 
stituent in the training set should be used. If the constituents Humor 
in the training set are not completely known, errors in the Fifteen samples of artificial aqueous humor were prepared 
solution of the model may result. with physiologic levels of glucose (97 mgidl), ascorbate (16 
Implicit methods utilize information only from the con- 40 mgidl), lactate (84 mgidl), and urea (36 mg.dl) in normal 
stituent of interest. These methods do not deduce any of the saline. Ethanol was added to these samples to achieve a final 
pure spectra present within a test sample. They can compute ethanol concentration ranging from 0 to 0.5%. Raman 
the concentration of the constituent of interest within the test spectra were acquired for each of the 15 samples in quartz 
sample directly from information derived from a training set cuvettes. Eleven Raman spectra of each sample were col- 
of mixture spectra with a known value of concentration for 4s lected using the Kaiser 785 nm spectrometer. The incident 
the constituent of interest. Care should be taken in devel- power of 15 mW for 20 seconds was utilized. The spectrum 
oping implicit calibration models to ensure that other con- of each sample was normalized by dividing each spectra by 
stituents in the training set are not collinearly related to the the area of the hydrogen bonding region in the 40Ck600 
constituent of interest. Partial least squares (PLS) and prin- cm-’ range. Each collected spectrum was then subtracted 
cipal component analysis (PCA) followed by principal com- SO from a spectrum of artificial aqueous humor with 0% ethanol 
ponent regression (PCR) are well known implicit methods (FIG. 32). 
that can provide good performance in the assessment of A PLS training model was developed using 10 Raman 
ethanol and/or its metabolites or other analyte of interest in spectra collected for each of 15 samples. The eleventh 
applications evaluating a selected region of the eye. PLS and spectra collected for each sample was treated as an 
PCR calibration models employ a set of mixture spectra ss “unknown” and its concentration was predicted using the 
from typical samples of the fluid of interest along with the PLS training model. Using only two factors in this model, 
concentration of the constituent of interest. the standard error of prediction (SEP) was 23 mg/dL, and the 
Knowledge of the pure spectra of the constituent(s) of correlation coefficient (R2) was 0.99935. Additionally, all 
interest, particularly ethanol and/or its metabolites, is rela- samples were incorporated into a PLS model and tested 
tively easily obtained. However, the implicit methods dis- 60 using cross-validation by using a leave-one-out round robin 
cussed above may not be able to incorporate this information approach. The Standard error of cross-validation (SECV) 
in their calibration models. The explicit models can incor- and correlation coefficient were 0.019 mgidL and 0.9991, 
porate this information, but spectral information from a respectively. Predicted (Raman measured) vs. actual ethanol 
plethora of other possible contaminants may make imple- concentrations are shown in FIG. 33. 
mentation difficult. Andrew Berger recently developed a 65 FIG. 32 illustrates normalized spectra for various levels of 
method known as hybrid linear analysis (HLA), which has ethanol in artificial aqueous humor at wave numbers ranging 
been shown to provide better accuracy than PLS with a from 70Ck1700 cm-’ and amplitude (in arbitrary units). FIG. 
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32 shows the normalized mixture spectrum and pure spectra While the present invention is illustrated, for example, 
of ethanol and its metabolites, acetaldehyde and acetate, with reference to the Raman spectral anaylzer module 350 
mixed in high equimolar quantities so the spectral features being an application program in FIG. 35, as will be appre- 
and relative Raman cross section of each could be easily ciated by those of skill in the art, other configurations may 
compared (measured concentration versus actual concentra- 5 also be utilized while still benefiting from the teachings of 
tion Of '% 33 is a graph Of PLS-measured the present invention. For example, the module 350 may 
ethanol concentration plotted with respect to actual ethanol also be incorporated into the operating system 352, the 110 
device drivers 358 or other such logical division of the data concentration in aqueous solution. 
i o  not be construed as limited to the configuration of FIG. 35, solutions of ethanol, acetaldehyde, acetic acid, and mixed metabolites across a range of wave numbers between 
7oe1700 with amplitude in arbitrary units, FIG, 34 shows which is intended to encompass any configuration capable of 
that the Raman spectra for 0.333M aqueous solutions of carrying Out the 'perations described herein. 
ethanol, acetaldehyde, and acetic acid each have similar In certain embodiments, the module 350 includes corn- 
Raman cross-sections. The spectrum of a mixture of the 
three metabolites is a sum of the individual spectra, dem- is quantifying the concentration of at least one selected analyte 
onstrating adherence to the Beer-Lambert law. of interest based on a predetermined statistical calibration 
Mathematical addition of the spectra of the pure constitu- model that identifies and analyzes certain particular wave 
ents results in a curve that is virtually identical to the numbers of interest. The module 350 may comprise at least 
measured spectra of the mixed sample. Therefore, the mix- one of  (a) partial least squares model; and (b) a hybridized 
ture of these constituents obeys the Beer-Lambert law in 20 linear model of the Raman spectra of the analyte of interest. 
aqueous solution. Thus, as contemplated by embodiments of The statistical model can be configured so that the module 
the present invention, PLS and/or HLAmodels can measure 350 evaluates a subset of the wave numbers (of pre-selected 
the concentrations of ethanol and/or its metabolites in the wave numbers) chosen so that they provide sufficient data 
spectral sample from a signal of mixed constituents (to about the amount of analyte present in the sample without 
determine blood and/or brain (or cerebral spinal fluid) zs requiring sampling of the entire wave number spectrum. In 
34 the Raman spectra for 0.333M aqueous processing system 305, Thus, the present invention should 
puter program code for the presence Of 
concentration). 
FIG. 35 is a block diagram of exemplary embodiments of 
data processing systems that illustrates systems, methods, 
and computer program products in accordance with embodi- 
ments of the present invention. The processor 310 commu- 
nicates with the memory 314 via an addressidata bus 348. 
The processor 310 can be any commercially available or 
custom microprocessor. The memory 314 is representative 
of the overall hierarchy of memory devices containing the 
software and data used to imalement the functionalitv of a 
particular embodiments, the wave numbers can be in the 
range of between about 700-1700 cm-l. 
The module 350 can be configured to detect chemical 
signatures, or quantify levels in the blood and/or brain of 
30 selected analytes, including, but not limited to, ethanol 
and/or its metabolites, glucose, or other desired analyte. In 
particular embodiments, the module 350 includes a math- 
ematical model for obtaining spectra and analyzing the 
spectra to determine the concentration (blood and/or brain) 
35 of ethanol. acetaldehvde. and acetic acid. The model mav 
, I  
data processing system 305. The memory 314 can include, 
but is not limited to, the following types of devices: cache, 
ROM, PROM, EPROM, EEPROM, flash memory, SRAM, 
and DRAM. 
analyze a plurality of predetermined narrow (less than about 
200 cm-l, and typically less than about 100 cm-l) segments 
in the Raman signal (selectively excluding regions that may 
shift due to increase or decrease in vivo concentration). The 
As shown in FIG. 35. the memorv 314 mav include 40 module 350 can include comauter urogram code that can 
several categories of software and data used in the data 
processing system: the operating system 352; the application 
programs 354; the inputioutput (I/O) device drivers 358; 
module of a Raman spectral analyzer configured to analyze 
at least one selected analyte of interest by evaluating the 
spectra of a selected region in the eye 350; and the data 356. 
The data 356 can include reference Raman spectrum signal 
data of the selected analyte(s) at a variety of concentrations 
as well as the Raman spectrum data being interrogated 362 
which mav be obtained in substantiallv real-time from a 
I V  
normalize the data by dividing the spectra of the ethanol, 
acetaldehyde and acetic acid by the area under the curve of 
a selected portion of the spectrum. In certain embodiments, 
the normalization is carried out using spectra data associated 
45 with the hydrogen-bonding region in the 400-600 cm-I 
range of the collected Raman response signal. The module 
350 can also include computer program code for evaluating 
the retina or iris for identity purposes as discussed above (the 
identification program code and equipment may be also held 
SO in a seaarate module). 
Raman spectrometer or signal acquisition system 320. As The data/processor structure or devices shown and 
will be appreciated by those of skill in the art, the operating described with respect to FIG. 35 may also be used to 
system 352 may be any operating system suitable for use implement other computer program products to carry out 
with a data processing system. certain operations of any of the embodiments described 
routines accessed through the operating system 352 by the An I/O data port can be used to transfer information 
application programs 354 to communicate with devices such between the data processing system 310 and the Raman 
as I/O data port(s), data storage 356 and certain memory 314 spectrometer or signal acquisition system 320 or another 
components and/or the image acquisition system 320. The computer system or a network (e.g., the Internet) or to other 
application programs 354 are illustrative of the programs 60 devices controlled by the processor. The computer program 
that implement the various features of the data processing code with the module 350 may be held in a device proximate 
system and preferably include at least one application that the spectrometer 320 or remotely. For remote configurations, 
supports operations according to embodiments of the present the signal data may be wirelessly relayed for evaluation. 
invention. Finally, the data 356 represents the static and These components may be conventional components such as 
dynamic data used by the application programs 354, the 65 those used in many conventional data processing systems, 
operating system 352, the I/O device drivers 358, and other which may be configured in accordance with the present 
software programs that may reside in the memory 314. invention to operate as described herein. 
The I/O device drivers 358 typically include software ss herein. 
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While the present invention is illustrated, for example, 
with reference to particular divisions of programs, functions 
and memories, the present invention should not be construed 
as limited to such logical divisions. Thus, the present inven- 
tion should not be construed as limited to the configuration s 
of FIG. 35 but is intended to encompass any configuration 
capable of carrying out the operations described herein. 
The flowcharts and block diagrams of certain of the 
figures herein illustrate the architecture, functionality, and 
operation of possible implementations of probe cell estima- IO 
tion means according to the present invention. In this regard, 
each block in the flow charts or block diagrams represents a 
module, segment, or portion of code, which comprises one 
fied logical function(s). It should also be noted that in some IS 
alternative implementations, the functions noted in the 
illuminating an aqueous humor of a subject with an 
optical excitation beam, wherein the excitation beam 
wavelength is selected to generate a resonant Raman 
spectrum of the selected analyte; 
detecting a resonant Raman spectrum corresponding to 
the illuminated aqueous humor; and 
identifying the presence, absence and/or the concentration 
of the selected analyte in the subject based on said 
detecting step. 
2.Amethod according to claim 1, wherein the wavelength 
3. A method according to 
is between about 400 nm-600 nm. 
analyte is a chemotherapeutic agent. 
analyte is an antifungal agent. 
5 ,  A method according to claim 1, wherein the selected 
analyte has a chemical structure having at least one of a 
‘3 wherein the 
or executable instructions for implementing the speci- 4. A method according to ‘3 wherein the 
may Occur Out Of the Order noted in the figures. For carbon-carbon bond and/or a carbon double bond, the 
example, two blocks shown in succession may in fact be method further comprising monitoring at least one peak of 
executed substantially concurrently or the blocks may some- interest in the detected Raman spectrum associated with the 
times be executed in the reverse order, depending upon the 20 carbon-carbon bond and/or the double carbon bond of the 
functionality involved. selected analyte chemical structure. 
In summary, embodiments of the present invention are 6. A method according to claim 1, wherein the selected 
directed to intermittent, semi-continuous, or continuous analyte has a chemical structure having a carbon double 
monitoring of systemic levels of analytes of interest, such as bond, the method further comprising monitoring the 
ethanol and its metabolites, with Raman spectroscopy. This zs detected Raman spectrum associated with the carbon double 
can be with techniques that are non-invasive or minimally bond of the selected analyte chemical Structure, and wherein 
invasive. In addition, the devices used to carry out the the excitation wavelength is between about 40Ck514 nm. 
interrogation of the biosample (i.e, AH) can be miniaturized 7. A method according to claim 6, wherein the selected 
for portability. These devices can have the capability of analyte comprises amphotercin B or a substantial chemical 
real-time data recording and telemetry for communication 30 equivalent, and/or metabolites, constituents or derivatives 
with integrated data analysis systems. Such systems, with thereof. 
remote data analysis, can allow research on human behavior, 8. A method according to claim 6, wherein the selected 
physiology, evaluation of the efficacy of drug and social analyte comprises fenretinide or a substantial chemical 
therapies with regard to inhibiting or preventing alcohol equivalent, and/or metabolites, constituents or derivatives 
consumption and the like. 
The foregoing is illustrative of the present invention and 9. A method according to claim 1, wherein the excitation 
is not to be construed as limiting thereof. Although a few 
exemplary embodiments of this invention have been 10. A method according to claim 1, further comprising: 
described, those skilled in the art will readily appreciate that comparing the Raman spectrum from said detecting step 
many modifications are possible in the exemplary embodi- 40 to a priori reference spectra corresponding to different 
ments without materially departing from the novel teachings concentrations of a plurality of different concentrations 
and advantages of this invention. Accordingly, all such of the selected analyte. 
modifications are intended to be included within the scope of 11. A method according to claim 1, wherein the selected 
this invention as defined in the claims. In the claims, analyte comprises at least one selected drug, pharmaceutical 
means-plus-function clauses, where used, are intended to 45 agent, metabolite, derivative or constituent thereof, and 
cover the structures described herein as performing the wherein the step of identifying comprises determining a 
recited function and not only structural equivalents but also concentration level in the micromolar range. 
equivalent structures. Therefore, it is to be understood that 12. A method according to claim 1, wherein the selected 
the foregoing is illustrative of the present invention and is analyte comprises at least one selected drug, pharmaceutical 
not to be construed as limited to the specific embodiments SO agent, metabolite, derivative or constituent thereof, and 
disclosed, and that modifications to the disclosed wherein the step of identifying comprises determining a 
embodiments, as well as other embodiments, are intended to concentration level in the nanomolar range. 
be included within the scope of the appended claims. 13. A method according to claim 1, wherein the identi- 
The statements characterizing one or more of the priority fying step comprises analyzing selected Raman spectra 
applications as a “continuation-in-part’’ application of a ss residing within 700-1700 cm-I of the resonant Raman 
prior application listed under the “Related Applications” spectrum to determine the presence and/or concentration of 
section above is used to indicate that additional subject the selected analyte. 
matter was added to the specification of the prior application 14. A method according to claim 13, wherein a plurality 
but does not necessarily mean that the entire invention of selected narrow regions in the resonant Raman spectrum 
described and claimed in the present application is not 60 are analyzed to determine the concentration of the analyte in 
supported in full by the prior application(s). the subject. 
The invention is defined by the following claims, with 15. A method according to claim 1, wherein the identi- 
equivalents of the claims to be included therein. fying step comprises determining a blood level concentra- 
We claim: tion of the selected analyte in the subject. 
1. A non-invasive method for identifying the presence of 65 16. A method according to claim 1, wherein the identi- 
fying step comprises determining a brain or cerebral spinal 
fluid concentration of the selected analyte in the subject. 
35 thereof. 
wavelength is between about 400-408 nm. 
and/or the concentration of a selected analyte in a subject, 
comprising: 
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17. A non-invasive method for identifying the presence of 
and/or the concentration of a selected analyte in a subject, 
comprising: 
illuminating a selected region in the eye of a subject with 
an optical excitation beam, wherein the excitation beam 
wavelength is selected to generate a resonant Raman 
spectrum of the selected analyte; 
detecting a resonant Raman spectrum corresponding to 
the selected illuminated region of the eye; and 
identifying the presence, absence and/or the concentration 
of the selected analyte in the subject based on said 
detecting step, 
wherein the detecting step is carried out to obtain a first 
resonant Raman spectrum of the subject before admin- 
istering a selected treatment and then to obtain a second 
resonant spectrum after administration of the selected 
treatment, and wherein the identifying step comprises 
subtracting baseline signatures of data from the second 
resonant Raman spectrum using data from the first 
resonant Raman spectrum. 
18. An evaluation apparatus for identifying the presence 
and/or concentration of a selected analyte in a subject, 
comprising: 
means for illuminating an aqueous humor with an optical 
excitation beam, wherein the optical excitation beam 
has a wavelength that is at least about 400 nm, resides 
within the absorption spectrum, and that generates a 
resonant Raman spectrum of a selected analyte in the 
aqueous humor of a subject; 
means for focusing the excitation beam into the subject so 
that the aqueous humor is illuminated; 
means for detecting a resonant Raman spectrum of the 
selected analyte from the illuminated aqueous humor; 
and 
means for identifying the presence and/or concentration 
of the selected analyte in the subject based on data 
obtained from the detecting means. 
19. An apparatus according to claim 18, wherein the 
means for identifying includes computer program code that 
determines the concentration level of the selected analyte 
using statistical analytical partial least squares. 
20. An apparatus according to claim 18, wherein the 
means for identifying includes computer program code that 
determines the concentration level of the selected analyte 
using statistical analytical hybrid linear analysis. 
21. An apparatus according to claim 18, wherein the 
apparatus is configured to detect micromolar ranges of 
concentrations of the selected analyte in the aqueous humor. 
22. An apparatus according to claim 18, wherein the 
apparatus is configured to detect nanomolar ranges of con- 
centrations of the selected analyte in the aqueous humor. 
23. An apparatus according to claim 18, wherein the 
apparatus is configured to determine blood concentrations of 
the selected analyte. 
24. An apparatus according to claim 18, wherein the 
apparatus is configured to determine brain, intracranial, 
and/or cerebral spinal fluid level concentrations. 
25. An apparatus according to claim 18, wherein the 
selected analyte is a pharmaceutical agent. 
26. An apparatus according to claim 18, wherein the 
means for illuminating is configured to generate an excita- 
tion signal wavelength that is between about 400 nm-600 
nm. 
27. An apparatus according to claim 26, wherein the 
excitation wavelength is between about 40Ck514 nm. 
28. An apparatus according to claim 27, wherein the 
excitation wavelength is between about 40Ck408 nm. 
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29. An apparatus according to claim 18, wherein the 
selected analyte is a chemotherapeutic agent. 
30. An apparatus according to claim 18, wherein the 
selected analyte is an antifungal agent. 
31. An apparatus according to claim 18, wherein the 
selected analyte has a chemical structure having at least one 
of a carbon-carbon bond and/or a carbon double bond, the 
apparatus comprising computer program code for analyzing 
at least one peak of interest in the detected resonant Raman 
spectrum associated with the carbon-carbon bond and/or the 
carbon double bond of the selected analyte chemical struc- 
ture. 
32. An apparatus according to claim 18, wherein the 
selected analyte comprises amphotercin B or a substantial 
chemical equivalent and/or metabolites, constituents, or 
derivatives thereof. 
33. An apparatus according to claim 18, wherein the 
selected analyte comprises fenretinide or a substantial 
chemical equivalent and/or metabolites, constituents, or 
derivatives thereof. 
34. An apparatus according to claim 18, wherein the 
means for identifying includes computer program code for 
comparing the resonant Raman spectrum to a priori refer- 
ence spectra corresponding to different concentrations of a 
plurality of different concentrations of the selected analyte. 
35. An apparatus according to claim 34, wherein the 
reference spectra comprise a plurality of different resonant 
Raman spectra generated for the selected analyte at different 
concentrations based on in vitro samples thereof. 
36. An evaluation apparatus for identifying the presence 
and/or concentration of a selected analyte in a subject, 
comprising: 
means for illuminating a selected region of the eye with 
an optical excitation beam, wherein the optical excita- 
tion beam has a wavelength that is at least about 400 
nm, resides within the absorption spectrum, and that 
generates a resonant Raman spectrum of a selected 
analyte in a subject; 
means for focusing the excitation beam into a selected 
region in the eve of the subject so that the selected 
region is illuminated; 
means for detecting a resonant Raman spectrum corre- 
sponding to the illuminated selected region of the eye; 
and 
means for identifying the presence and/or concentration 
of the selected analyte in the subject responsive to the 
detecting means 
wherein the means for identifying comprises computer 
program code that competes a first resonant Raman 
spectrum of the subject taken before administering a 
selected treatment to a second resonant Raman spec- 
trum taken after administration of the selected 
treatment, and subtracts baseline signature data from 
the second resonant Raman spectrum using data from 
the first resonant Raman spectrum. 
37. An apparatus according to claim 18, wherein the 
means for identifying comprises computer program code for 
analyzing selected Raman spectra residing within 700-1700 
cm-I of the resonant Raman spectrum to determine the 
presence and/or concentration of the selected analyte. 
38. An apparatus according to claim 18, wherein the 
means for identifying comprises computer program code in 
a computer readable medium that analyzes a plurality of 
selected narrow regions in the resonant Raman spectrum to 
determine the concentration of the analyte in the subject. 
39. An apparatus according to claim 18, wherein the 
means for illuminating is configured to confocally deliver 
the excitation beam to the aqueous humor of the eye of the 
subject. 
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40. An apparatus according to claim 18, wherein said 
means for identifying comprises computer program code for 
sampling selected wave numbers of the resonant Raman 
spectrum using a partial least squares statistical model. 
41. An apparatus according to claim 18, wherein said 
means for identifying comprises computer program code for 
sampling selected wave numbers of the resonant Raman 
spectrum using a hybrid linear analysis statistical model. 
42. An apparatus according to claim 18, wherein said 
excitation beam has a power rating of about 2 mW that 
illuminates the aqueous humor for about 10 seconds. 
43. An apparatus according to claim 18, wherein the 
means for identifying comprises computer program code 
that subtracts a fluorescence spectrum from the resonant 
Raman spectrum to produce a difference spectrum. 
44. An apparatus according to claim 18, wherein the 
apparatus is configured to detect a plurality of different 
selected analytes of interest. 
45. An apparatus according to claim 44, further compris- 
ing computer program code of reference data of spectra for 
each analyte of interest comprising spectra generated from a 
Raman spectra training set based on at least 10 in vitro 
aqueous humor samples for each analyte of interest with 
each of the at least 10 samples including different amounts 
of the analyte therein, and an analyte level corresponding to 
each of the samples. 
46. An apparatus according to claim 45, wherein the 
computer program reference data are generated from a 
training set of Raman spectra corresponding to at least 20 
aqueous humor samples of varying concentrations of ana- 
lytes therein far each of a plurality of different selected 
analytes and an identified blood level, and brain or cerebral 
spinal fluid level of said analyte of interest for each of said 
samples. 
47. An apparatus according to claim 18, wherein said 
apparatus comprises a portable housing that holds the com- 
ponents therein, and wherein the housing includes a user 
interface that is configured and sized to fit onto and/or rest 
against the head of the subject during operation. 
48. An apparatus according to claim 47, wherein said 
housing is configured and sized to be a band held device. 
49. A non-invasive method for identifying the presence 
and/or the concentration of a selected analyte in a subject 
and identifying the subject comprising: 
illuminating an aqueous humor of a subject with an 
optical excitation beam; 
detecting a resonant Raman spectrum corresponding to 
the aqueous humor; 
determining the presence, absence and/or the concentra- 
tion of the selected analyte in the subject based on said 
detecting step; 
obtaining a biometric reading of the iris or retinal struc- 
ture of at least one of the subject’s eyes; and 
identifying the subject based on the biometric reading. 
50. A non-invasive method according to claim 49, 
wherein the obtaining step is carried out by obtaining an 
image of the iris and comparing the image to predetermined 
iris characteristics. 
51. An apparatus for determining the presence of and/or 
the concentration of a selected analyte in a subject and 
confirming the identity the subject comprising: 
means for illuminating an aqueous humor of a subject 
with an optical excitation beam; 
means for detecting a resonant Raman spectrum corre- 
sponding to the aqueous humor; 
means for determining the presence and/or the concen- 
tration of the selected analyte in the subject responsive 
to said means for detecting; and 
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means for obtaining a biometric reading of the iris or 
52. A portable apparatus for determining the presence of 
and/or the concentration of a selected analyte in a subject 
5 and confirming the identity the subject comprising: 
retinal structure to identify the subject. 
a portable housing; 
an illumination source in the housing configured to gen- 
erate an optical excitation beam into an aqueous humor 
of a subject; 
a detector in the housing configured to obtain a resonant 
Raman spectrum from the aqueous humor and deter- 
mine the presence and/or the concentration of a 
selected analyte in the subject; and 
a biometric reader in the housing configured to interrogate 
an iris or retinal structure of the eye of the subject to 
identify the subject. 
53. An apparatus according to claim 52, wherein the 
biometric reader is configured to obtaining an image of the 
2o iris and comparing the image to predetermined iris charac- 
teristics. 
54. A non-invasive method for identifying the presence of 
and/or the concentration of a selected analyte in a subject, 
comprising: 
illuminating a vitreous humor of a subject with an optical 
excitation beam, wherein the excitation beam wave- 
length is selected to generate a resonant Raman spec- 
trum of the selected analyte; 
detecting a resonant Raman spectrum corresponding to 
the illuminated vitreous humor; and 
identifying the presence, absence and/or the concentration 
of the selected analyte in the subject based on said 
detecting step. 
55. Amethod according to claim 54, wherein die selected 
analyte is a chemotherapeutic agent. 
56. Amethod according to claim 54, wherein the selected 
analyte is an antifungal agent. 
57. Amethod according to claim 54, wherein the selected 
40 analyte has a chemical structure having at least one of a 
carbon-carbon bond and/or a carbon double bond, the 
method further comprising monitoring at least one peak of 
interest in the detected Raman spectrum associated with the 
carbon-carbon bond and/or the double carbon bond of the 
58. Amethod according to claim 54, wherein the selected 
analyte comprises amphotercin B or a substantial chemical 
equivalent, and/or metabolites, constituents or derivatives 
thereof. 
59. Amethod according to claim 54, wherein the selected 
analyte comprises fenretinide or a substantial chemical 
equivalent, and/or metabolites, constituents or derivatives 
thereof. 
60. Amethod according to claim 54, wherein the detecting 
ss step is carried out to obtain a first resonant Raman spectrum 
of the subject before administering a selected treatment and 
then to obtain a second resonant spectrum after administra- 
tion of the selected treatment, and wherein the identifying 
step comprises subtracting baseline signatures of data from 
60 the second resonant Raman spectrum using data from the 
first resonant Raman spectrum. 
61. A method according to claim 54, wherein a plurality 
of selected narrow regions in the resonant Raman spectrum 
are analyzed to determine the concentration of the analyte in 
25 
30 
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45 selected analyte chemical structure. 
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